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INTRODUCTION 
Dental implants are widely used to restore missing teeth or to serve as abutments for a 
bridge, partial dental or complete denture. It is reported that 69% of adults in the U.S. ages 35 to 44 
have lost at least one permanent tooth due to trauma, periodontitis, a failed root canal, or tooth 
decay. By age 74, 26% of adults have lost all of their permanent teeth. (1) In 2008, the global 
dental implant market increased to $3.4 billion dollars, while the market for traditional crowns and 
bridges decreased to $4.4 billion dollars. The market value of dental implants is anticipated to 
reach $8.1 billion by 2015. (1)  
Rationale for Dental Implant Application 
Dental implants have many advantages over transitional crowns, bridges or dentures. 
Dental implants are able to preserve tooth structures, because there is no need to remove adjacent 
abutment teeth structures for a bridge. It is not necessary to consider the risk of recurrent caries in 
dental implants, while caries is considered to be the most frequent reason for failure of existing 
restorations such as onlays, crowns, and bridges. (2) Implants can provide much more stability and 
retention of implant supported prosthesis than traditional tooth/tissue -borne partial dentures and 
tissue borne complete dentures. (3) In addition, the most important aspect of dental implants is to 
preserve alveolar bone. Carlsson et al. have reported that marginal periimplant bone loss over a 
10-year observation period was less than 1 mm for both mandible and maxillae. (4) However, the 
loss of alveolar bone after just 1 year following tooth extraction reached 6 mm in width and 1.2 in 
height. (5) Because of alveolar bone preservation, dental implants can be used to restore and 
maintain the gingival tissue emergence profile in the maxillary esthetic zone after anterior tooth 
extraction. (6) Furthermore, the property of the prevention of implants from alveolar bone loss 
may be a key rationale for its more than 90% long-term survival rate.  
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Major Clinical Challenges for Dental Implants 
Dental implants require sufficient alveolar bone, both in width and in length,  to acquire 
adequate primary stability, and to eventually exert its support function. In some cases such as 
severely atrophic edentulous mandibles and thin maxillary sinus floor, without bone augmentation, 
implant treatment is not an option for patients with severe alveolar bone absorption.  In addition, 
bone loss also results in some problems in the anterior maxilla for esthetic reasons. (6) On the other 
hand, patients with implant placement should wait 3 to 6 months clinically for successful 
osseointegration formation and final permanent restoration. Therefore, how to augment alveolar 
bone and shorten the clinical waiting time are two major clinical challenges for dental 
implantology.  
Growth Factor Gene Therapy To Enhance Implant Osseointegration 
Traditional techniques for enhancing bone formation for dental implant placement include 
bone autografts, allografts or guided bone regeneration.(7) The use of osteogenic growth factors 
such as PDGF to regenerate tooth-supporting and peri-implant bone in preclinical animal models 
(8-12)
 
and in early human trials (13, 14)has offered significant potential for periodontal 
regenerative medicine. However, outcomes of these therapies are limited in terms of regeneration 
and predictability.  The utilization of gene therapy to control the release and bioavailability of 
osteogenic growth factors (GFs) offers potential for tissue engineering periodontal and 
peri-implant bone defects. (15)  
Despite many of the positive results using growth factors for alveolar bone regeneration, 
drug instability at the site of delivery contributes to the need of pharmacologic dosing, which is 
limited by local and systemic toxicity. (16)
 
The therapeutic delivery of growth factors requires a 
well-characterized delivery system to safely target the factors to the wound. A few human trials 
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using GFs reported to date have utilized superphysiological doses of GFs that result in 
“dose-dumping” of potent biologics in the wound site. (17-19) This use of bolus delivery can lead 
to systemic toxicity,(20)
 
likely through cytokine diffusion into the bloodstream. (21) Although 
clinical trials have offered encouraging initial results, the degree of tooth-supporting tissue 
regeneration achieved from these studies is suboptimal.  Systematic reviews of the literature of 
current periodontal therapies suggest these treatments result in only slight improvements in bone 
regeneration (usually <50% regeneration) and for horizontal defects (<20%) improvement. (22, 23) 
A possible reason for these minimal results may be related to the short half-life of biomolecules 
delivered to osseous tooth-supporting defects in vivo, as well as the minimal levels of bioactive 
factors that may be available in tissue banked bone. Our recent work in the area (see attached 
publications) demonstrates: 1. the potency of Ad/PDGF-B to stimulate tooth-supporting bone; (24) 
2: Our ability to develop and utilize a model of dental implant osseointegration in small animals 
for gene therapy applications; (25)
 
and 3: our ability to demonstrate safety (26)
 
and has offered 
many significant advances using gene therapy to repair tooth-supporting defects. Therefore, gene 
transfer offers significant potential to improve growth factor delivery to dental implant-associated 
bone defects.  
PDGF Biological Functions and Gene Therapy 
 
Platelet derived growth factor (PDGF) is a member of a multifunctional polypeptide family, 
which is composed of A, B, C and D polypeptide chains that form homo- or heterodimeric 
molecules.(27)  PDGF binds to two structurally-related intrinsic tyrosine kinase receptors 
(PDGF-R and PDGF-R) and subsequently exerts its biological effects on cell migration, 
proliferation, extracellular matrix synthesis, and anti-apoptosis.(28-32)  PDGF not only plays a 
crucial role in the development of the heart, kidney, and vasculature,(33) but also contributes to 
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tissue repair.(15)  PDGF- and - receptors are induced in regenerating periodontal soft and hard 
tissues.(34, 35)  In addition, PDGF initiates tooth-supporting periodontal ligament (PDL) cell 
chemotaxis,(36) mitogenesis,(37) matrix synthesis,(38, 39) and attachment to tooth dentinal 
surfaces.(40) More importantly, in vivo application of PDGF alone or in combination with 
insulin-like growth factor-I (IGF-I) results in partial repair of periodontal tissues as shown in 
preclinical and clinical investigations.(10, 13, 41, 42)  Recently, PDGF is FDA-approved for the 
treatment of neurotrophic diabetic ulcers(43) and for promoting bone repair of periodontal osseous 
defects, (44, 45) indicating that PDGF has an important impact not only on soft tissues, but also on 
osseous tissues. PDGF gene transfer has been shown to stimulate gingival fibroblast, PDL and 
tooth-lining cell (cementoblast) mitogenesis and proliferation above that of continuous PDGF 
administration in vitro.(46, 47)  Adenovirus-mediated PDGF-B gene transfer accelerates gingival 
soft tissue wound healing in an ex vivo wound repair model.(48)  Therefore,  we will explore in this 
study the significant potential of adenovirus-mediated PDGF-B gene transfer to improve bone 
regeneration at rat dental implant-associated bone defects.  
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SPECIFIC AIMS and HYPOTHESIS 
Specific Aim 1: To evaluate safety of PDGF gene local delivery approach. Hypothesis: the 
controlled local delivery of PDGF-B gene by recombinant adenovirus vectors will be localized 
without distant organ involvement.  Safety of any clinical approaches is the first consideration. 
Periodontal alveolar bone defects were created in rat mandibles, and recombinant adenoviruses 
encoding PDGF-B with collagen carrier were added into the defects. Collagen carrier alone was 
used as a negative control. At designated time points during 3-35 days postdelivery, rats were 
sacrificed, and tissue in the defects and many organs were harvested. DNA in tissues and organs 
were extracted. The biodistrubition of PDGF adenovirus vectors were evaluated by real-time PCR. 
In addition, the changes of tissues and organs after PDGF gene delivery were observed 
histologically.  
Specific Aim 2: To determine the potential of PDGF gene delivery approach to regenerate 
alveolar bone around titanium implants in rats.  Hypothesis: The controlled delivery of growth 
factor genes will stimulate new bone formation in the defects around dental implants. Large 
osteotomy bone defects were created in rats following tooth extraction and treated with 
recombinant adenoviruses encoding PDGF-B, or human recombinant PDGF-BB, or collagen 
carrier alone. Simultaneous with gene delivery, endosseous dental implants were placed. The 
kinetics and extent of bone volume achieved adjacent to the dental implants were measured using 
microCT, back-scattered EM, and conventional histomorphometric analysis.  
Results from these studies will aid in the better understanding of the role of sustained growth factor 
gene delivery on peri-implant wound repair.  The long-term goal of this project will optimize and 
validate gene therapeutic approaches to provide sufficient evidence to consider the development of 
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a pivotal study using PDGF gene delivery to promote bone regeneration of dental implant defects 
in humans.  
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EXPERIMENT DESIGN, MATERIALS, and METHODS 
Experiment Design for Specific Aim 1 
In order to investigate the biodistribution of PDGF adenovirus vectors after local delivery, 
periodontal osseous defects were created at the mandibles of a total of 144 (75 male, and 69 female) 
10-week old Sprague-Dawley rats (weighing 250-300 grams). These defects were treated with 
Ad/PDGF-B at 5.5 x 108 pfu/ml (low-dose), Ad/PDGF-B at 5.5 x 109 pfu/ml (high-dose), and 
collagen matrix alone, respectively. At day 1, 2, 3, 4, 5, 7, 14, 21, 28, and 35 after surgery, the rats 
were sacrificed.  Tissue in defects, blood, the sunmandibular lymph nodes, axillary lymph nodes, 
brain, lung, heart, liver, spleen, kidney, and testes from male rats, as well as ovaries from female 
rats were harvested.  One part of the tissues and organs was used to extract DNA. The 
biodistrubition of PDGF adenovirus vectors were evaluated by real-time PCR.  The other was used 
to prepare histology routine sections.  
Adenovirus Vectors Preparation 
E1-, E3-deleted human adenovirus serotype 5 vectors encoding human platelet-derived 
growth factor-B (Ad/PDGF-B) under control of the cytomegalovirus promoter were employed in 
this study. Titers of virus stocks were determined on embryonic kidney 293 cells by plaque assay 
and expressed as the plaque-forming units (pfu) per milliliter. Two different doses of adenoviral 
vectors were examined in this study, 5.5x108 pfu/ml and 5.5x109 pfu/ml. These dose levels were 
equivalent to Ad-PDGFB concentrations previously described.(24) 
Preparation of Adenovirus-Gene Activated Matrix. 
 Ad-PDGF-B were dialyzed into GTS buffer (2.5% glycerol, 25 mM NaCl, 20 mM Tris, 
pH 8.0) and formulated in bovine fibrillar type I collagen matrix (Matrix Pharmaceutical Inc., 
Fremont, CA, USA) at a final concentration of 2.6%. 
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Periodontal Alveolar Bone Wound Model and Ad/PDGF-B Treatment 
All animal experiments were approved by the University of Michigan Institutional Animal 
Care and Use Committee. A total of 144 (75 male, and 69 female) 10-week old Sprague-Dawley 
rats (weighing 250-300 grams) were utilized in this study. Three different adenovirus-gene 
activated matrices were prepared immediately prior to surgery, containing 5.5 x 108 pfu/ml 
(low-dose), 5.5 x 109 pfu/ml (high-dose) of AdPDGF-B, and collagen matrix alone. For surgical 
operations, the animals were anesthetized with ketamine (50 mg/kg) and xyzaline (10 mg/kg), 
followed by analgesia as needed with buprenex (0.1-0.5 mg/kg, Reckitt Benckiser Healthcare Ltd., 
Hull, England). A standardized 3 x 2 x 1 mm osseous defect was created in the buccal plate 
overlying the mandibular first molar and second molar tooth roots as previously described (49). 
The exposed roots were carefully denuded of periodontal ligament, cementum, and superficial 
dentin. Then 20l of adenovirus/collagen matrix were delivered to the defects, filling them to 
entirety. The wounds were closed by suturing the superficial musculature layers and 
approximating the skin by surgical clips. The rats received analgesics on the following day as 
needed for up to 7 days post-surgery. The animals also received supplemental antibiotics 
(ampicillin 268 mg/L of dextrose in distilled water) for 7 days. The surgical clips were removed 10 
days following surgery.  
Tissue Harvesting, Histological, and Histopathological Observations  
Upon sacrifice at designated time points, the submandibular lymph nodes, axillary lymph 
nodes, brain, lung, heart, liver, spleen, kidney, and testes from male rats, and the entire tissue 
within defect area as well as ovaries from female rats were harvested. The ipsilateral organs were 
chosen, and for organs with abundant DNA (heart, lung, liver, spleen, kidney, sex organs, and 
brain), sectioning was done at the center of each specimen. Half of the selected tissues were then 
preserved in a -80◦C freezer for DNA extraction, and the remaining half were fixed with 10% 
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formalin for 24 hours and transferred to 75% ethanol for subsequent histological and 
histopathological analysis. The defect mandibulae were decalcified with 10% acetic acid, 4% 
formaldehyde, and 0.85% NaCl for 3 weeks. Then, decalcified mandibulae and the organ 
specimens were dehydrated in step gradients of ethanol and embedded in paraffin. Sections from 
two different regions (border and central level of defect) were made in mandibular samples and 3-6 
slices from the central-cut sections (5-8 mm in thickness). Hematoxylin and eosin staining was 
performed on all histological sections followed by pathological examination. A thorough 
histopathological examination was performed for all sections. 
Quantitative Polymerase Chain Reaction (qPCR) Assay.  
Quantitative TaqMan PCR was used to determine the vector copy number of AdPDGF-B in 
the bloodstream and organs. The primers used for quantitative real time PCR (QPCR) bridging the 
vector backbone and PDGF-BB prepro region were: sense -- 
5’-GGATCTTCGAGTCGACAAGCTT-3’; anti-sense 
--5’-ATCTCATAAAGCTCCTCGGGAAT-3’; internal fluorogenic probe --  
5’-CGCCCAGCAGCGATTCATGGTGAT-3’. QPCR was performed by using TaqMan 
Universal PCR Master Mix (Applied Biosystems). Briefly, a 30 l PCR reaction was prepared 
with 500 ng DNA and 1.5l mixture of gene fluorogenic probe and primers. The thermal 
conditions were: 50°C 2 min, 95°C 10 min followed by 45 cycles of 95°C, 15 sec and 60°C, 1 min, 
and the resulting amplicon was detected by ABI Prism 7700 sequence detection instrument 
(Applied Biosystems). The standard curve was determined by using a range of 101 to 105 
AdPDGF-B particles (regression correlation coefficient > 95%). The possibility of cross-reactivity 
was evaluated by adding adenoviral vector encoding PDGF-A, PDGF-1308 (dominant-negative 
mutant PDGF), bone morphogenetic protein-7, noggin, bone sialoprotein, Luciferase, and GFP for 
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comparison.  No enhancement or inhibition of signal was noted when tissues were spiked with 
these vectors. 
For blood DNA, the samples were collected from 6 rats per gender in the four groups 
(high-dose AdPDGF-B, low-dose AdPDGF-B, collagen matrix only, and no treatment) prior to 
surgery, and throughout 35 days after gene delivery . 50 l whole blood was isolated and DNA was 
obtained by QIAamp DNA blood Mini kit (QIAGEN Inc., Valencia, CA, USA). For organ and 
tissue DNA, the total tissue in the defect area and surrounding musculature, submandibular lymph 
node, axillary lymph nodes, brain, lung, heart, liver, kidney, spleen, and sex organs (testes and 
ovaries) were excised from 3 rats in each of the three groups (high-dose AdPDGF-B, low-dose 
AdPDGF-B, and collagen matrix only) post-sacrifice, and triplicate experiments were performed. 
The time points analyzed were from 3 to 35 days. Each PCR reaction contained 500 ng test DNA 
without spiking. Pre-study experiments demonstrated expected signal enhancement using 
AdPDGF-B spiking (500 copies per reaction, data not shown). The limitation of detection was 30 
copies per 500 ng test DNA for all the specimens. 
Experiment Design for Specific Aim 2 
In order to evaluate the effects of PDGF gene delivery approach on dental implant 
osseointegration, a total of 82 male Spraque-Dawley rats were used. Based on the power analysis 
calculations from a previous similar study, 6-8 animals were required per treatment per time point. 
(24)  Four weeks after the maxillary first molar were extracted bilaterally, a well-type osteotomy 
was created. Following implant placement, four treatments were performed: .5x109 pfu/ml 
Ad-Luc as a negative control, 5.5x108 pfu/ml Ad/PDGF-B, 5.5x109 pfu/ml Ad/PDGF-B, or 0.3 
mg/ml rhPDGF-BB as a positive control. At day 10, 14 and 21 after implantation, the maxillae 
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containing implant were harvested, examined by microCT, BS-SEM, histology and 
histomorphometry. 
Preparations of Recombinant Adenovirus Vectors and Delivery Matrix 
  Please see the above. 
Well-type Osteotomy Creation, Implant Placement and Treatments 
All animal procedures followed the guidelines from the Committee on Use and Care of 
Animals of the University of Michigan. The maxillary first molars were extracted bilaterally 4 
weeks prior to dental implant installation. After healing, an osteotomy was created using a custom 
drill-bit. The drill-bit was designed with a 0.95 mm diameter, 1 mm long-apical portion and a 2.2 
mm diameter, 1 mm long at the coronal aspect. The apical part of the drill created an osteotomy for 
initial fixation and the coronal part of the drill created a circumferential osseous defect prior to 
dental implant installation. A custom cylinder-type titanium mini-implant (gift of Institut 
Straumann AG, Basel, Switzerland), 1 mm-in-diameter and 2 mm-in-depth, was press-fit into the 
surgically-created socket( Fig 1. A). The remaining defect was then filled with the type I collagen 
matrix containing 5.5x109 pfu/ml Ad-Luc, 5.5x108 pfu/ml Ad-PDGF-B, 5.5x109 pfu/ml 
Ad-PDGF-B, or 0.3 mg/ml rhPDGF-BB (Fig1. B). Ad-Luc has not previously exhibited biological 
activities in dentoalveolar defects (24)and served as control group in this study. The surgical area 
was covered by gingival tissue and closed using butyl cyanoacrylate (Periacryl®, Glustitch Inc., 
Point Roberts, WA, USA). The vital fluorochrome dye, calcein (10 mg/kg), was injected 
intra-muscularly after 3 days, and antibiotics (268 mg/L ampicillin in 5% dextrose water) were 
provided in the first 7 days post-operation. 
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Fig 1. A.  Dental Implant Osteotomy Defect Model for Gene Delivery.  “Well-type” osteotomy 
defects were created that measured 1 mm in depth and 2 mm coronally (left panel).  The titanium 
dental implant was press fit into position (middle panel), followed by the delivery of the 2.6% 
collagen matrix containing either Ad/PDGF-B or collagen gel alone (right panel). B.  High 
magnification photos from the surgical operation corresponding to 1A taken at 10x magnification 
including defect creation (left panel), dental implant placement (middle) and gene delivery (right). 
BS-SEM, Histology and Histomorphometry 
Maxillae containing the implants were harvested upon sacrifice, with one side of maxillae 
taken for backscattered SEM and histology while the contralateral maxillae were used for 
microCT after removing implant to avoid metal scattering influence. The specimens were fixed in 
50% ethanol for at least 72 hours and subsequently embedded in epoxy resin. The specimens were 
then sectioned in the longitudinal direction relative to the implants using a diamond saw blade 
(Crystalite Co., Westerville OH, USA), then polished to achieve a 50-100 m final thickness. The 
tissue mineralization was evaluated under the backscattered mode on Qanta F1B SEM with 45x 
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magnification, calibrated with aluminum and carbon discs (50), and transferred to physical density 
using bone substitute radiographic phantoms (Gammex Inc., Middleton WI, USA). The 
photographs were then segmented and threshholded by Otsu’s adaptive technique (51). To 
eliminate any metal scattering effect, the measured bone-implant interface was defined as the 
horizontal distance 5m from the outermost homogenous high-intensity area. The defect borders 
were projected using the calcein fluorescent images. Bone-area fractions (BAF, the ratio of 
newly-formed bone in the defect to the entire defect area) and Tissue mineral density within the 
defect (TMD, the average grayscale level of mineralized tissue within the defect area) were 
measured from backscattered SEM images. Next, histologic staining by methylene blue was 
performed, with the acid fuschin utilized as the counterstaining. Bone-implant contact (BIC, the 
ratio of the length of bone contacting the titanium to the entire length of titanium interface with the 
defect area) and defect fill (DF, the ratio of bone-occupied area to the entire defect area) were 
measured. 
MicroCT 3-D Evaluations 
After implant removal, micro-CT scans were performed using an eXplore Locus SP 
Micro-CT system (GE HealthCare, London, ON, Canada) and reconstructed to voxel size of 
18x18x18 m3. The spatial relationship of the mini-implant and surrounding tissues was then 
analyzed using a customized MATLAB® (Mathworks Inc., Natick, MA, USA) algorithm. The 
images were segmented with a threshold determined by Otsu’s adaptive technique (51), and 
several parameters were quantitatively evaluated within the osseous defect areas: (1) Bone volume 
fraction (BVF): the volume of mineralized tissue within the osseous wound divided by the volume 
of osseous wound; (2) Tissue mineral density (TMD): the mineral content of the 
radiographic-defined mineralized tissue within the osseous wound divided by the volume of 
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osseous wound; (3) Bone mineral density (BMD): the mineral density within the 
radiographic-defined mineralized tissue in the osseous wound.  
Statistical Analysis 
One way ANOVA with Tukey post hoc test was used to analyze the difference of 
parameter data obtained from histomorphometry performed on BS-SEM photos or MicroCT 3-D 
images of biopsies at each groups. The statistical difference was considered with a p-value of < 
0.05. 
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RESULTS, DISCUSSIONS, and CONCLUSIONS 
 
 
A: Adenovirus Encoding Human Platelet-Derived Growth Factor-B Delivered to Alveolar Bone 
Defects Exhibits Safety and Biodistribution Profiles Favorable for Clinical Use (Chang et al. Hum 
Gene Ther. 2009 May;20(5):486-96.)                                                                                              
Results and Discussion are on pages 19 ~ 25. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adenovirus Encoding Human Platelet-Derived
Growth Factor-B Delivered to Alveolar Bone Defects Exhibits
Safety and Biodistribution Profiles Favorable for Clinical Use
Po-Chun Chang,1,2 Joni A. Cirelli,1 Qiming Jin,1 Yang-Jo Seol,1,3 James V. Sugai,1 Nisha J. D’Silva,1
Theodora E. Danciu,1 Lois A. Chandler,4 Barbara A. Sosnowski,4 and William V. Giannobile1,2
Abstract
Platelet-derived growth factor (PDGF) gene therapy offers promise for tissue engineering of tooth-supporting
alveolar bone defects. To date, limited information exists regarding the safety profile and systemic biodis-
tribution of PDGF gene therapy vectors when delivered locally to periodontal osseous defects. The aim of this
preclinical study was to determine the safety profile of adenovirus encoding the PDGF-B gene (AdPDGF-B)
delivered in a collagen matrix to periodontal lesions. Standardized alveolar bone defects were created in rats,
followed by delivery of matrix alone or containing AdPDGF-B at 5.5108 or 5.5109 plaque-forming units=ml.
The regenerative response was confirmed histologically. Gross clinical observations, hematology, and blood
chemistries were monitored to evaluate systemic involvement. Bioluminescence and quantitative polymerase
chain reaction were used to assess vector biodistribution. No significant histopathological changes were noted
during the investigation. Minor alterations in specific hematological and blood chemistries were seen; however,
most parameters were within the normal range for all groups. Bioluminescence analysis revealed vector dis-
tribution at the axillary lymph nodes during the first 2 weeks with subsequent return to baseline levels.
AdPDGF-B was well contained within the localized osseous defect area without viremia or distant organ
involvement. These results indicate that AdPDGF-B delivered in a collagen matrix exhibits acceptable safety
profiles for possible use in human clinical studies.
Introduction
Platelet-derived growth factor (PDGF), a member ofa multifunctional polypeptide family, is composed of
disulfide-bonded A, B, C, or D polypeptide chains to form a
homo- or heterodimeric molecule (Andrae et al., 2008). PDGF
is highly expressed in inflammatory cells, damaged bone,
platelets, and mesenchymal cells (Southwood et al., 2004).
PDGF mediates mitogenesis and chemotaxis of mesenchy-
mal cells and osteoblasts through tyrosine-phosphorylated
signaling pathways (Ronnstrand and Heldin, 2001; Fiedler
et al., 2004). In oral tissues, PDGF also facilitates chemotaxis,
matrix deposition, and attachment of periodontal ligament
cells (Nishimura and Terranova, 1996; Haase et al., 1998).
Delivery of PDGF-BB has also demonstrated enhancement
of periodontal wound repair (Cooke et al., 2006) and re-
generation preclinically (Giannobile et al., 1994, 1996; Park
et al., 2000) and in humans (Howell et al., 1997; Nevins et al.,
2005).
Although exogenous growth factors improve the soft and
hard tissue healing response, more sophisticated delivery
methods are necessary to ensure adequate protein concen-
tration and specific cell targeting to defect sites (Ramseier et al.,
2006; Cotrim and Baum, 2008). Recombinant adenoviruses
(Ads) have been used as gene delivery vectors because of
several unique features: (1) Ads have high transduction effi-
ciency in both dividing and nondividing cells; (2) Ads do
not induce apparent phenotypic changes in transduced cells;
and (3) Ads do not integrate into the host genome and re-
main episomal (Gu et al., 2004). Compared with recombinant
growth factors, adenovirus encoding PDGF gene sequences
(AdPDGF) can successfully transduce cells, prolong growth
1Department of Periodontics and Oral Medicine, School of Dentistry, University of Michigan, Ann Arbor, MI 48109.
2Department of Biomedical Engineering, College of Engineering, University of Michigan, Ann Arbor, MI 48109.
3Department of Periodontology, School of Dentistry, Seoul National University, Seoul 110–749, South Korea.
4Tissue Repair Co., San Diego, CA 92121.
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factor expression, and induce downstream signaling path-
ways (Chen and Giannobile, 2002).
Adenoviral vectors administered to the head and neck for
salivary gland repair have been previously studied and are
now in clinical development (Cotrim et al., 2007; Voutetakis
et al., 2008). Matrix-mediated delivery of DNA vectors has
the potential to localize the vector and transgene products
within the immediate delivery site (Chandler et al., 2000). We
have previously shown that AdPDGF-B delivery in colla-
gen significantly improves cementogenesis and osteogenesis
in vivo ( Jin et al., 2004). A preclinical investigation using the
AdPDGF-B=collagen combination in a rabbit dermal wound
model revealed robust localized wound healing responses
with minimal systemic vector dissemination (Gu et al., 2004).
On the basis of our current knowledge, no existing data
describe the systemic effects of adenoviral vector delivered to
the osseous craniofacial complex. In this study we sought to
evaluate the safety profile for the local, collagen matrix-
mediated delivery of AdPDGF-B for the promotion of alveolar
bone healing. Vector copy number and expression at the de-
fect site and various organs were quantified, and systemic
hematology and blood chemistry were evaluated. In combi-
nation with histological findings, the data in the present study
further support the clinical development of matrix-enabled
gene therapy for periodontal wound regeneration.
Materials and Methods
Adenoviral vectors
E1-,E3-deleted human adenovirus serotype 5 vectors en-
coding transgenes under the control of the cytomegalovirus
promoter were employed in this study. Adenovirus encoding
human platelet-derived growth factor-B (AdPDGF-B) and
adenovirus encoding firefly luciferase (AdLuc) were used for
gene transfer. Titers of viral stocks were determined on em-
bryonic kidney 293 cells by plaque assay and expressed as
plaque-forming units (PFU) per milliliter. Two different doses
of adenoviral vectors were examined in this study: 5.5108
and 5.5109 PFU=ml in 20 ml of collagen matrix. These dose
levels were equivalent to AdPDGF-B concentrations previ-
ously described ( Jin et al., 2004).
Preparation of adenovirus gene-activated matrix
AdPDGF-B and AdLuc were dialyzed into GTS buffer
(2.5% glycerol, 25mM NaCl, 20mM Tris; pH 8.0) and for-
mulated in bovine fibrillar type I collagen matrix (Matrix
Pharmaceutical, Fremont, CA) to a final concentration of 2.6%.
Periodontal alveolar bone wound model
and AdPDGF-B treatment
All animal experiments were approved by the Institutional
Animal Care and Use Committee of the University of Michi-
gan (Ann Arbor, MI). A total of 144 (75 male, and 69 female)
10-week-old Sprague-Dawley rats (weighing 250–300g) were
used in this investigation. The general timeline, grouping cri-
teria, and study design are shown in Fig. 1A and total gender
distributions for each experiment are described separately.
Two different adenovirus gene-activated matrices were
prepared immediately before surgery, containing AdPDGF-B
at 5.5108 PFU=ml (low dose), AdPDGF-B at 5.5109 PFU=ml
(high dose), or collagen matrix alone. For surgical operations,
the animals were anesthetized with ketamine (50mg=kg) and
xylazine (10mg=kg), followed by analgesia as needed with
buprenorphine (Buprenex, 0.1–0.5mg=kg; Reckitt Benckiser
Healthcare, Hull, UK). Standardized 321mm osseous de-
fects were created in the buccal plate overlying the mandi-
bular first molar and second molar tooth roots as previously
described ( Jin et al., 2003). The exposed roots were carefully
denuded of periodontal ligament, cementum, and superficial
dentin. Twenty microliters of adenovirus=collagen matrix
was then delivered to the defects, filling them to entirety. The
wounds were closed by suturing the superficial musculature
layers and approximating the skin by surgical clips. The rats
received analgesics on the next day as needed for up to 7 days
postsurgery. The animals also received supplemental antibi-
otics (ampicillin, 268mg=liter of dextrose in distilled water) for
7 days. The surgical clips were removed 10 days after surgery.
Six rats without any surgical interventions (no treatment)
were also included to compare the effect on body homeostasis
of the surgical procedure versus no treatment.
Body weight and clinical observations
Twenty-four male rats were distributed equally to four
groups (high-dose AdPDGF-B, low-dose AdPDGF-B, colla-
gen matrix only, and no treatment). The body weight of those
animals was measured during the first 3 weeks. Clinical ob-
servation was focused on evaluation of the gross signs of
swelling and lesions on days 3–35 as noted in Fig. 1A.
Tissue harvesting, and histological
and histopathological observations
On sacrifice, the submandibular lymph nodes, axillary
lymph nodes, brain, lung, heart, liver, spleen, kidney, and
testes (frommale rats), and the entire tissue within defect area
as well as ovaries (from female rats), were harvested with
sterile scissors for each of the specific tissues and organs. The
instruments were sterilized between tissue harvests, using a
glass bead sterilizer. The ipsilateral organs were chosen, and
for organs with abundant DNA (heart, lung, liver, spleen,
kidney, sex organs, and brain), sectioning was done at the
center of each specimen. Half of the selected tissues were then
preserved in a 808C freezer for DNA extraction, and the
remaining half were fixed with 10% formalin for 24 hr and
transferred to 75% ethanol for subsequent histological and
histopathological analysis. The defect mandibulae were dec-
alcified with 10% acetic acid, 4% formaldehyde, and 0.85%
NaCl for 3 weeks. Decalcified mandibulae and the organ
specimens were then dehydrated in step gradients of ethanol
and embedded in paraffin. Sections from two different regions
(border and central level of defect) were made in mandibular
samples and three to six slices from the central-cut sections
(5–8mm in thickness). Hematoxylin and eosin staining was
performed on all histological sections, followed by patholog-
ical examination. The time points for analyses were from days
3 to 35 as described in Fig. 1A. A thorough histopathological
examination was performed for all sections.
Kinetics of luciferase expression
by AdLuc=GAM in vivo
Adenovirus encoding luciferase (AdLuc) was formulated
at concentrations of 5.5108 PFU=ml (low dose, n¼ 6, 3 per
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gender) and 5.5109 PFU=ml (high dose, n¼ 6, 3 per gender)
in 20ml of collagen matrix. Luciferase expression within each
of the animals was measured with an in vivo imaging system
(Xenogen=Caliper Life Sciences, Alameda, CA). To standard-
ize the images, the cutoff threshold was set at 5000p=sec=
cm2=sr to reduce the background signals, and the yield
threshold was set at 13,000 p=sec=cm2=sr. The amplitude of
luciferase expression was calculated by subtracting the in-
tensity of luciferin signal before and 12–15min after luciferin
(Promega,Madison,WI) injection (4mg of luciferin per 25 g of
body weight). The time points for evaluation are described in
Fig. 1A.
Hematology and blood chemistry
All procedures were performed by the animal health di-
agnostic laboratory in the Unit for Laboratory Animal Medi-
cine (ULAM) at the University ofMichigan. Twenty-fourmale
rats were distributed equally into four groups (high-dose
AdPDGF-B, low-dose AdPDGF-B, collagen alone, and no
treatment), and bloodwas drawn from the day before surgery
through 35 days postoperation (Fig. 1A). Fifty microliters of
whole blood from each rat was placed into a tube containing
EDTA anticoagulant for hematological specimens and a
complete blood cell count (CBC) with automatic differential
was performed. Serum (200 ml) was drawn from each animal
and the chemical parameters examined included alkaline
phosphatase, calcium, phosphorus, creatinine kinase, albu-
min, globulin, total protein, blood urea nitrogen (BUN), cre-
atinine, aspartate transaminase (AST), alanine transaminase
(ALT), bilirubin, total bilirubin (T. bilirubin), amylase, glu-
cose, and cholesterol.
Quantitative polymerase chain reaction assay
Quantitative TaqMan polymerase chain reaction (PCR)
was used to determine the vector copy number of AdPDGF-B
in the bloodstream and organs. The primers used for
FIG. 1. General study design and body weight change over time. (A) Five treatment groups (5.5108 PFU=ml
AdLuc=collagen, 5.5109 PFU=ml AdLuc=collagen, 5.5108 PFU=ml AdPDGF-B=collagen, 5.5109 PFU=ml AdPDGF-B=
collagen, and collagen matrix only) were investigated. The observation time points were over a period of 35 days on a weekly
basis; two animals in 5.5109 PFU=ml AdLuc=collagen group were observed for 75 days. Nontreated animals (neither
surgical defect nor adenovirus–collagen mixture application) were also included in the experiment to evaluate systemic
involvement. (B) All the surgically treated animals experienced transient body weight loss in the first few days posttreatment
but thereafter gained weight continuously throughout the study period.
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quantitative real-time PCR (qPCR) bridging the vector back-
bone and PDGF-B prepro region were as follows: sense, 50-
GGATCTTCGAGTCGACAAGCTT-30; antisense, 50-ATCTC
ATAAAGCTCCTCGGGAAT-30; internal fluorogenic probe,
50-CGCCCAGCAGCGATTCATGGTGAT-30. qPCR was per-
formed with TaqMan universal PCR master mix (Applied
Biosystems, Foster City, CA). Briefly, a 30-ml PCR was pre-
pared with 500 ng of DNA and a 1.5-ml mixture of gene
fluorogenic probe and primers. The thermal conditions were
as follows: 508C for 2min, 958C for 10min, followed by 45
cycles of 958C for 15 sec and 608C for 1min, and the resulting
amplicon was detected with an ABI PRISM 7700 sequence
detection instrument (Applied Biosystems). The standard
curve was determined with a range of 101 to 105 AdPDGF-B
particles (regression correlation coefficient, >95%). The pos-
sibility of cross-reactivity was evaluated by adding adenovi-
ral vector encoding PDGF-A, PDGF-1308 (dominant-negative
mutant PDGF), bone morphogenetic protein-7, noggin, bone
sialoprotein, luciferase, and green fluorescent protein (GFP)
for comparison. No enhancement or inhibition of signal was
noted when tissues were spiked with these vectors.
For blood DNA, the samples were collected from 6 rats
per gender (total of 12 per group) in the four groups (high-
dose AdPDGF-B, low-dose AdPDGF-B, collagen matrix
only, and no treatment) before surgery, and throughout 35
days after gene delivery (Fig. 1A). Fifty microliters of whole
blood was isolated and DNA was obtained with a QIAamp
DNA blood mini kit (Qiagen, Valencia, CA). For organ and
tissue DNA, total tissue in the defect area and surrounding
musculature, submandibular lymph node, axillary lymph
nodes, brain, lung, heart, liver, kidney, spleen, and sex or-
gans (testes and ovaries) was excised from three rats in
each of the three groups (high-dose AdPDGF-B, low-dose
AdPDGF-B, and collagen matrix only) postsacrifice, and
triplicate experiments were performed. The time points an-
alyzed were from 3 to 35 days (Fig. 1A). Each PCR contained
500 ng of test DNA without spiking. Prestudy experiments
demonstrated expected signal enhancement with AdPDGF-B
spiking (500 copies per reaction; data not shown). The limit
of detection was 30 copies per 500 ng of test DNA for all the
specimens.
Statistical analysis
Analysis of variance (ANOVA) was used to evaluate the
differences in body weights and hematological and chemical
parameters between experimental and control groups. Test
groups were evaluated for time-dependent dynamics with
collagen and nonsurgical groups, using Bonferroni posttests,
and the significance was assessed by repeated-measures
ANOVA. Results are presented as the mean SD of mea-
surements, with a p value less than 0.05 being considered
statistically significant.
Results
Clinical observations and body weight
All animals survived throughout the entire experimental
period and among all surgically treated animals, no signifi-
cant adverse events were noted beyond local swelling at the
treatment sites, presumably caused by the surgical proce-
dures. Body weight changes were normalized, using day 0 as
baseline, and the measures of weight change were evaluated
as fractions relative to baseline weight. Results showed that
after surgical treatment, all animals experienced slight weight
loss within the first 2 days; however, they consistently gained
weight over the course of the study. No significant weight
changes were found among the three surgical groups at any
time point (Fig. 1B).
Histology and histopathology
Two weeks after surgery, early bone formation could be
observed within the defect area (Fig. 2A, top). Nearly com-
plete bone bridging of the alveolar bone wounds was noted
in both AdPDGF-B-treated groups, whereas there was lim-
ited bridging in the collagen-only animals. Cementogenesis
could be seen in both AdPDGF-B-treated groups at 2 weeks
but not in the collagen matrix group, and the defects treated
with high-dose (5.5109 PFU=ml) AdPDGF-B revealed more
cementum formation compared with the other groups (Fig.
2A, bottom). At 35 days, the bone had completely bridged
all of the defect area, and the fractions of defect fill be-
came consistent in all animals. Animals receiving high-dose
AdPDGF-B demonstrated greater evidence of cementogenesis
along the tooth root (Fig. 2B).
Macroscopic evaluations of the harvested organs revealed
no meaningful changes except mild enlargement of the sub-
mandibular lymph nodes in AdPDGF-B-treated (both high-
dose and low-dose) and collagen matrix-only groups within
the first week postsurgery. Evaluation of histological sections
showed occasional but mild inflammatory infiltration in
lymph nodes, spleen, and liver in all groups. However, no
significant histopathological signs were noted beyond the
suspected alterations associated with the surgical operation.
In particular, no evidence of viral inclusions was observed for
any of the evaluated tissues and organs.
Hematology and blood chemistry
Blood was analyzed from each animal before surgery and
through 35 days postoperation (Fig. 1A). Also, blood from six
animals in the no-treatment group was collected for com-
parison. All parameters for hematology and blood chemistry
were consistent among groups and were generally within the
normal range. Although there were some minor changes, we
found no significant differences in complete blood count
(CBC) and clinical chemistry parameters in any treatment
group throughout the period of observation (Tables 1 and 2).
There were several animals in both the high-dose and low-
dose groups that revealed significant changes in amylase;
however, the majority of the values were within the normal
range. On day 28, animals in the low-dose group demon-
strated significant elevation in serum glucose, but those levels
returned to the baseline range by day 35.
Vector expression by bioluminescence
Whole body image analysis of animals treated with
AdLuc=collagen matrix revealed a transduction and distribu-
tion profile from adenoviral gene delivery over the course of
the experiment. Bioluminescent luciferase expression was de-
tected in the head and neck region for all AdLuc=collagen-
treated animals (n¼ 6 per group), with the level of expression
higher in animals receiving high-dose AdLuc compared with
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the low-dose animals (Fig. 3A). For the low-dose AdLuc-
treated group, luciferase expression gradually decreased to
undetectable levels at the treated sites by 14 days without any
spreading to distant organs for time points thereafter (note in
Fig. 3A whole body imaging [top], some luminescence on day
28 on the animal’s right side). Results also showed gradually
decreasing expression of luciferase in the head and neck region
within 2 weeks in high-dose AdLuc-treated animals. Further,
the high-dose treated animals yielded a weak signal detected
in the axillary lymph node area of three animals, and one
animal showed liver expression at 1 week. However, after
2 weeks no signal was detected in any distant organs of any
animal (Fig. 3B). To further investigate the persistent, low-level
expression of AdLuc signal in two high-dose treated ani-
mals, bioluminescence imaging was performed until sacrifice
at 75 days posttreatment. The defect mandible, surrounding
musculature, axillary lymph nodes, liver, and gonadal organs
were harvested and images were captured for biolumines-
cence quantification. Results revealed that a weak signal was
restricted to only the surrounding musculature (<10p=sec=
mm2=sr), and no signal was detected in the defect site (data
not shown). In addition, no significant gender differences in
AdLuc expressionwere revealed; however, a somewhat lower
signal was noted on day 1 in the head and neck region of
female rats receiving high-dose AdLuc treatment ( p< 0.05;
data not shown).
FIG. 2. PDGF gene delivery promotes periodontal tissue regeneration in vivo. (A) Limited bone formation and bridging had
occurred by 14 days in wound treated with collagen matrix only compared with AdPDGF-B=collagen-treated defects. Top:
Original magnification, 40. Bottom: Higher power view (original magnification, 200) of tooth=cementum=periodontal
ligament (PDL)=bone interfaces outlined in red in the top row. More newly formed cementum structure (blue arrows) was
observed in high-dose (5.5109 PFU=ml) AdPDGF-B=collagen-treated sites. (B) At 35 days, defect treated with AdPDGF-B at
5.5109 PFU=ml demonstrated a significant amount of root cementum compared with defect treated with collagen matrix
only. Red arrowheads indicate the edges of exposed tooth dentin surface; blue arrows, new cementum; black asterisks, tooth
roots; yellow asterisks, the area of PDL. (All images are in transverse orientation and stained with hematoxylin and eosin.)
490 CHANG ET AL.
20
T
a
b
l
e
1.
H
e
m
a
t
o
l
o
g
ic
a
l
A
n
a
l
y
se
s
fo
r
A
d
P
D
G
F
-B
D
e
l
iv
e
r
y
t
o
A
l
v
e
o
l
a
r
B
o
n
e
D
e
fe
c
t
sa
H
em
at
ol
og
ic
al
pa
ra
m
et
er
b
B
ef
or
e
su
rg
er
y
D
ay
3
D
ay
7
D
ay
1
4
C
ol
L
-A
d
H
-A
d
C
ol
L
-A
d
H
-A
d
C
ol
L
-A
d
H
-A
d
C
ol
L
-A
d
H
-A
d
W
B
C
(K
=
ml
)
12
.5
3
(1
.8
4)
12
.8
7
(2
.2
1)
13
.9
9
(2
.9
8)
13
.0
8
(1
.9
8)
8.
49
1
(1
.4
28
)
16
.2
7
(2
.2
9)
12
.5
7
(4
.7
5)
12
.0
7
(3
.9
7)
16
.9
0
(2
.1
9)
16
.0
7
(3
.1
5)
13
.0
1
(2
.7
9)
14
.6
4
(0
.8
6)
N
eu
tr
o
p
h
il
(K
=
ml
)
3.
08
1
(0
.8
87
)
4.
18
4
(0
.9
10
)
4.
53
4
(1
.3
43
)
3.
49
3
(0
.6
65
)
2.
44
8
(0
.5
59
)
4.
98
5
(0
.6
60
)
4.
36
5
(2
.1
70
)
2.
78
1
(1
.0
32
)
6.
01
9
(0
.6
78
)
6.
59
9
(2
.2
93
)
4.
13
4
(1
.2
28
)
4.
81
1
(0
.6
63
)
L
y
m
p
h
o
cy
te
(K
=
ml
)
8.
64
1
(1
.4
81
)
7.
90
8
(1
.5
93
)
8.
75
3
(1
.5
95
)
8.
78
4
(1
.4
49
)
5.
48
4
(0
.9
49
)
10
.1
6
(1
.2
59
)
7.
45
5
(2
.6
74
)
8.
49
1
(2
.7
54
)
9.
65
1
(1
.6
73
)
8.
68
3
(1
.8
70
)
8.
02
5
(1
.5
75
)
8.
97
4
(0
.5
00
)
M
o
n
o
cy
te
(K
=
ml
)
0.
76
5
(0
.2
39
)
0.
74
5
(0
.1
66
)
0.
60
4
(0
.1
80
)
0.
73
5
(0
.2
20
)
0.
51
6
(0
.1
75
)
0.
84
1
(0
.1
69
)
0.
55
8
(0
.2
99
)
0.
76
4
(0
.3
12
)
1.
14
1
(0
.1
82
)
0.
68
7
(0
.0
79
)
0.
69
4
(0
.1
74
)
0.
71
1
(0
.1
12
)
E
o
si
n
o
p
h
il
(K
=
ml
)
0.
03
3
(0
.0
23
)
0.
02
1
(0
.0
15
)
0.
07
4
(0
.0
48
)
0.
05
6
(0
.0
48
)
0.
04
3
(0
.0
29
)
0.
13
4
(0
.0
75
)
0.
15
8
(0
.1
19
)
0.
02
9
(0
.0
16
)
0.
05
(0
.0
43
)
0.
07
3
(0
.0
79
)
0.
13
3
(0
.0
63
)
0.
08
3
(0
.0
96
)
B
as
o
p
h
il
(K
=
ml
)
0.
00
5
(0
.0
08
)
0.
00
9
(0
.0
10
)
0.
02
4
(0
.0
35
)
0.
00
8
(0
.0
10
)
0.
00
3
(0
.0
05
)
0.
02
6
(0
.0
36
)
0.
04
3
(0
.0
41
)
0.
00
9
(0
.0
08
)
0.
03
(0
.0
44
)
0.
02
7
(0
.0
48
)
0.
02
6
(0
.0
31
)
0.
01
6
(0
.0
38
)
R
B
C
(M
=
ml
)
7.
27
3
(0
.5
99
)
8.
16
4
(0
.4
88
)
6.
88
(0
.6
46
)
7.
74
5
(1
.2
10
)
6.
70
9
(0
.5
06
)
6.
22
3
(0
.4
26
)
5.
71
6
(1
.0
68
)
7.
60
6
(1
.2
13
)
7.
34
4
(0
.6
00
)
6.
76
3
(0
.4
81
)
7.
04
3
(0
.3
44
)
7.
34
4
(0
.2
24
)
H
b
(g
=
d
l)
14
.9
1
(0
.7
8)
17
.3
5
(1
.7
2)
13
.9
4
(1
.4
2)
15
.2
5
(2
.5
6)
13
.2
9
(1
.1
0)
12
.5
8
(0
.9
7)
11
.3
5
(2
.2
9)
15
.3
8
(1
.9
5)
15
.5
8
(1
.0
9)
13
.5
1
(0
.6
9)
14
.4
5
(0
.6
0)
15
.0
38
(0
.5
32
)
H
ct
(%
)
44
.9
1
(4
.5
3)
51
.2
4
(2
.9
8)
41
.7
6
(4
.0
9)
47
.2
(7
.6
7)
40
.4
3
(2
.8
8)
37
.6
4
(2
.3
1)
33
.5
(6
.3
7)
44
.6
6
(6
.5
8)
44
.7
4
(5
.6
9)
40
.5
4
(3
.4
0)
41
.7
5
(1
.4
6)
43
.8
9
(1
.1
8)
M
C
V
(fl
)
61
.7
(1
.8
6)
62
.7
9
(1
.2
0)
60
.6
7
(1
.3
7)
60
.9
(1
.5
3)
60
.3
1
(1
.7
4)
60
.5
4
(0
.7
3)
58
.5
2
(1
.1
4)
58
.8
5
(1
.3
7)
62
.8
5
(1
.1
3)
59
.8
9
(1
.8
0)
59
.3
6
(1
.2
0)
59
.7
9
(1
.1
8)
M
C
H
(p
g
)
20
.5
5
(0
.9
9)
21
.2
4
(1
.0
4)
20
.2
7
(0
.7
6)
19
.6
9
(0
.8
1)
19
.8
(0
.3
7)
20
.1
9
(0
.3
0)
19
.7
7
(0
.5
8)
20
.3
3
(1
.2
7)
21
.2
3
(0
.4
7)
20
.0
1
(0
.9
8)
20
.5
4
(1
.0
9)
20
.4
8
(0
.3
4)
M
C
H
C
(g
=
d
l)
33
.3
3
(1
.7
5)
33
.8
1
(1
.8
1)
33
.3
9
(0
.8
4)
32
.2
8
(0
.7
5)
32
.8
6
(1
.0
6)
33
.4
(0
.7
1)
33
.8
2
(1
.0
9)
34
.5
5
(1
.6
1)
34
.0
3
(1
.0
3)
33
.4
7
(1
.5
9)
34
.6
5
(1
.5
6)
34
.2
88
(0
.9
54
)
R
D
W
(%
)
15
.4
4
(0
.5
5)
16
.2
(0
.5
2)
15
.0
1
(0
.3
2)
16
.0
1
(0
.6
3)
15
.7
6
(0
.6
1)
15
.8
8
(0
.4
6)
15
.9
2
(0
.5
0)
17
.6
5
(0
.7
6)
16
.8
9
(0
.6
7)
16
.3
9
(0
,9
8)
16
.2
9
(0
.4
2)
16
.6
3
(0
.3
7)
A
bb
re
v
ia
ti
on
s:
C
o
l.
co
ll
ag
en
m
at
ri
x-
o
n
ly
g
ro
u
p
;
H
-A
d
,
h
ig
h
-d
o
se
(5
.5
1
09
P
F
U
=
m
l)
A
d
P
D
G
F
-B
-t
re
at
ed
g
ro
u
p
;
H
b
,
h
em
o
g
lo
b
in
;
H
ct
,
h
em
at
o
cr
it
;
L
-A
d
,
lo
w
-d
o
se
(5
.5
1
08
P
F
U
=
m
l)
A
d
P
D
G
F
-B
-t
re
at
ed
g
ro
u
p
;M
C
H
,m
ea
n
co
rp
u
sc
u
la
r
h
em
o
g
lo
b
in
;M
C
H
C
,m
ea
n
co
rp
u
sc
u
la
r
h
em
o
g
lo
b
in
co
n
ce
n
tr
at
io
n
;M
C
V
,m
ea
n
co
rp
u
sc
u
la
r
v
o
lu
m
e;
R
B
C
,r
ed
b
lo
o
d
ce
ll
s;
R
D
W
,r
ed
b
lo
o
d
ce
ll
d
is
tr
ib
u
ti
o
n
w
id
th
;W
B
C
,
w
h
it
e
b
lo
o
d
ce
ll
s.
a
n
¼
6
p
er
g
ro
u
p
.E
n
tr
ie
s
d
em
o
n
st
ra
te
th
e
av
er
ag
e
v
al
u
e
o
f
p
ar
am
et
er
s
fo
r
ea
ch
g
ro
u
p
;n
u
m
b
er
s
in
p
ar
en
th
es
es
in
d
ic
at
e
st
an
d
ar
d
d
ev
ia
ti
o
n
s.
N
o
si
g
n
ifi
ca
n
t
d
if
fe
re
n
ce
s
w
er
e
n
o
te
d
am
o
n
g
th
e
A
d
P
D
G
F
-
B
an
d
co
ll
ag
en
m
at
ri
x
g
ro
u
p
s
d
u
ri
n
g
ea
rl
y
ti
m
e
p
o
in
ts
,
as
w
el
l
as
b
ey
o
n
d
14
d
ay
s
(d
at
a
n
o
t
sh
o
w
n
).
b
K
=
ml
,
th
o
u
sa
n
d
s
p
er
m
ic
ro
li
te
r
(e
n
tr
y
1
03
);
M
=
ml
,
m
il
li
o
n
s
p
er
m
ic
ro
li
te
r
(e
n
tr
y
1
06
).
491
21
T
a
b
l
e
2.
C
l
in
ic
a
l
C
h
e
m
is
t
r
y
A
n
a
l
y
se
s
F
o
r
A
d
-P
D
G
F
-B
D
e
l
iv
e
r
y
a
C
li
n
ic
al
ch
em
is
tr
y
p
ar
am
et
er
B
ef
or
e
su
rg
er
y
D
ay
3
D
ay
7
D
ay
1
4
C
ol
L
-A
d
H
-A
d
C
ol
L
-A
d
H
-A
d
C
ol
L
-A
d
H
-A
d
C
ol
L
-A
d
H
-A
d
A
lb
u
m
in
(g
=
d
l)
2.
81
4
(0
.1
35
)
2.
76
3
(0
.1
30
)
2.
65
7
(0
.1
81
)
2.
65
(0
.6
48
)
2.
65
7
(0
.1
72
)
2.
82
5
(0
.1
16
)
2.
54
3
(0
.1
13
)
2.
95
(0
.1
41
)
2.
78
8
(0
.1
81
)
2.
78
6
(0
.1
77
)
2.
91
3
(0
.1
25
)
3.
13
3
(0
.2
34
)
A
L
P
as
e
(U
=
li
te
r)
26
0.
43
(2
3.
52
)
25
5
(5
3.
18
)
23
9
(3
1.
09
)
18
5.
5
(5
9.
34
)
23
8.
43
(3
5.
45
)
16
6.
63
(2
9.
61
)
20
0.
86
(3
7.
66
)
20
5.
75
(5
8.
94
)
15
3.
38
(2
7.
69
)
23
2.
29
(2
9.
19
)
23
2.
63
(4
2.
45
)
25
1.
67
(4
3.
48
)
A
L
T
(U
=
li
te
r)
67
.1
4
(8
.3
0)
89
(8
.4
5)
87
.2
5
(7
.5
0)
72
.8
8
(8
.9
2)
79
.8
6
(4
.0
6)
79
.8
8
(8
.1
5)
10
0.
57
(1
0.
47
)
79
.3
8
(9
.9
6)
81
(5
.0
4)
84
.8
6
(5
.0
5)
86
.5
(7
.5
8)
79
.5
(1
9.
99
)
A
m
y
la
se
(U
=
li
te
r)
18
81
.1
4
(1
86
.9
5)
18
31
(1
88
.3
6)
15
54
.1
7
(2
67
.6
1)
19
05
.3
8
(3
88
.6
1)
18
57
.4
3
(5
44
.4
9)
17
70
(2
51
.9
5)
24
94
.8
6
b
(8
44
.4
0)
17
05
.7
5
(3
10
.8
8)
17
85
.1
3
(3
28
.2
2)
19
90
.7
1
(5
25
.5
8)
18
79
.3
8
(1
95
.6
0)
20
85
.3
3
(4
4.
00
4)
A
S
T
(U
=
li
te
r)
71
.8
6
(9
.9
1)
79
.3
8
(9
.3
2)
79
.8
8
(8
.9
7)
69
.5
(2
0.
76
)
83
.5
(1
6.
55
)
69
.8
8
(5
.1
9)
12
6.
14
(1
11
.6
7)
77
.5
7
(1
3.
23
)
70
.5
(1
1.
43
)
66
.4
3
(1
1.
77
)
90
.5
(2
6.
46
)
93
.2
5
(1
6.
34
)
B
il
ir
u
b
in
(m
g
=
d
l)
20
.1
4
(3
.3
4)
19
.5
(3
.7
0)
19
(2
.1
6)
21
.2
5
(2
.4
9)
20
(2
)
22
.1
3
(2
.5
9)
24
.8
6
(1
.8
6)
21
.3
8
(2
.3
9)
19
.1
3
(1
.6
4)
22
.5
7
(1
.6
2)
23
.7
5
(3
.4
5)
24
.1
7
(1
.3
3)
C
al
ci
u
m
(m
g
=
d
l)
10
.1
1
(0
.2
5)
10
.2
9
(0
.1
9)
10
.1
6
(0
.2
8)
10
.5
4
(1
.3
0)
10
.2
3
(0
.2
8)
10
.4
9
(0
.1
5)
10
.4
1
(0
.2
5)
10
.3
5
(0
.2
3)
10
.3
5
(0
.1
2)
10
.8
6
(0
.2
4)
10
.2
8
(0
.1
8)
10
.8
3
(0
.2
3)
C
h
o
le
st
er
o
l
(m
g
=
d
l)
83
.2
9
(7
.1
3)
78
(9
.2
0)
63
.8
6
(1
1.
81
)
78
.7
1
(2
9.
37
)
80
.2
9
(8
.1
6)
90
(7
.0
1)
80
(6
.9
0)
80
.3
8
(7
.0
3)
81
.1
3
(2
.8
0)
84
.4
3
(1
0.
88
)
77
.3
8
(1
0.
32
)
82
.3
3
(5
.8
6)
C
re
at
in
e
k
in
as
e
(U
=
li
te
r)
16
6.
67
(2
8.
25
)
19
0.
63
(5
1.
90
)
17
6.
86
(4
7.
36
)
17
8.
5
(7
0.
13
)
25
9.
83
(1
33
.1
3)
14
2.
63
(3
3.
18
)
15
6.
20
(3
8.
46
)
24
4.
57
(1
06
.6
9)
21
9.
38
(6
4.
16
)
12
1.
71
(2
8.
96
)
18
6.
88
(6
1.
42
)
19
7.
75
(6
1.
41
)
C
re
at
in
in
e
(m
g
=
d
l)
0.
4
(0
.0
58
)
0.
35
(0
.0
53
)
0.
32
9
(0
.0
49
)
0.
36
3
(0
.0
52
)
0.
38
6
(0
.0
38
)
0.
4
(0
)
0.
38
6
(0
.0
38
)
0.
38
8
(0
.0
35
)
0.
3
(0
.0
53
)
0.
4
(0
)
0.
38
8
(0
.0
35
)
0.
62
9
(0
.3
99
)
G
lu
co
se
(m
g
=
d
l)
23
0.
43
(1
8.
39
)
22
7.
88
(2
7.
22
)
22
9
(3
5.
77
)
21
7.
65
(2
4.
22
)
22
1.
57
(1
9.
15
)
19
1
(3
3.
81
5)
24
5.
29
(5
3.
94
)
23
2
(2
9.
99
)
22
9.
88
(3
0.
19
)
19
2.
14
(7
.6
7)
21
2.
5
(3
9.
75
)
20
0.
4
(1
0.
69
)
P
h
o
sp
h
o
ru
s
(m
g
=
d
l)
7.
65
7
(0
.6
60
)
7.
4
(0
.4
90
)
6.
74
3
(0
.3
95
)
7.
22
5
(0
.5
85
)
6.
21
4
(0
.1
57
)
6.
66
3
(0
.4
34
)
6.
67
1
(0
.3
40
)
7.
65
(0
.5
37
)
7.
45
(0
.4
07
)
5.
9
(2
.6
2)
7.
32
5
(0
.4
86
)
6.
83
3
(0
.1
15
)
T
.
b
il
ir
u
b
in
(m
g
=
d
l)
0.
1
(0
)
0.
1
(0
)
0.
1
(0
)
0.
27
5
(0
.4
56
)
0.
11
4
(0
.0
38
)
0.
11
3
(0
.0
35
)
0.
1
(0
)
0.
17
5
(0
.1
39
)
0.
21
3
(0
.2
10
)
0.
1
(0
)
0.
11
3
(0
.0
35
)
0.
1
(0
)
T
o
ta
l
p
ro
te
in
(g
=
d
l)
5.
62
9
(0
.3
25
)
5.
62
5
(0
.2
05
)
5.
55
7
(0
.2
76
)
5.
95
(0
.6
80
)
5.
52
9
(0
.2
50
)
5.
92
5
(0
.1
28
)
5.
58
6
(0
.2
19
)
5.
86
3
(0
.2
50
)
5.
8
(0
.2
78
)
5.
94
3
(0
.1
90
)
5.
93
8
(0
.2
62
)
6.
44
3
(0
.3
51
)
G
lo
b
u
li
n
(g
=
d
l)
2.
81
4
(0
.2
27
)
2.
83
8
(0
.1
06
)
2.
88
6
(0
.1
07
)
3.
28
8
(1
.2
72
)
2.
95
7
(0
.1
62
)
3.
1
(0
.0
93
)
3.
04
3
(0
.1
51
)
2.
92
5
(0
.1
28
)
3.
02
5
(0
.1
28
)
3.
15
7
(0
.1
40
)
3.
01
3
(0
.1
46
)
3.
25
(0
.1
52
)
A
bb
re
v
ia
ti
on
s:
A
L
P
as
e,
al
k
al
in
e
p
h
o
sp
h
at
as
e;
A
L
T
,
al
an
in
e
tr
an
sa
m
in
as
e;
A
S
T
,
as
p
ar
ta
te
tr
an
sa
m
in
as
e;
C
o
l,
co
ll
ag
en
m
at
ri
x
-o
n
ly
g
ro
u
p
;
H
-A
d
,
h
ig
h
-d
o
se
(5
.5
1
09
P
F
U
=
m
l)
A
d
P
D
G
F
-B
-t
re
at
ed
g
ro
u
p
;
L
-A
d
,
lo
w
-d
o
se
(5
.5
1
08
P
F
U
=
m
l)
A
d
P
D
G
F
-B
-t
re
at
ed
g
ro
u
p
;
T
.
b
il
ir
u
b
in
,
to
ta
l
b
il
ir
u
b
in
.
a
A
ll
co
m
p
ar
is
o
n
s
ar
e
m
ad
e
w
it
h
re
fe
re
n
ce
to
th
e
co
ll
ag
en
m
at
ri
x
g
ro
u
p
.
E
n
tr
ie
s
d
em
o
n
st
ra
te
th
e
m
ea
n
v
al
u
e
o
f
p
ar
am
et
er
s
fo
r
ea
ch
g
ro
u
p
;
n
u
m
b
er
s
in
p
ar
en
th
es
es
in
d
ic
at
es
st
an
d
ar
d
d
ev
ia
ti
o
n
s.
S
er
u
m
am
y
la
se
fo
r
b
o
th
A
d
P
D
G
F
-B
-t
re
at
ed
g
ro
u
p
s
re
v
ea
le
d
si
g
n
ifi
ca
n
t
d
if
fe
re
n
ce
s
w
it
h
re
sp
ec
t
to
th
e
co
ll
ag
en
m
at
ri
x
g
ro
u
p
,
an
d
w
as
w
it
h
in
th
e
n
o
rm
al
ra
n
g
e
fo
r
ti
m
e
p
o
in
ts
b
ey
o
u
n
d
14
d
ay
s.
b
S
ig
n
ifi
ca
n
t
d
if
fe
re
n
ce
fr
o
m
co
ll
ag
en
m
at
ri
x
g
ro
u
p
(p
<
0.
05
;
n
¼
6
p
er
g
ro
u
p
).
492
22
Biodistribution by quantitative PCR
The specificity of our PCR primers and the sensitivity of the
assay were determined before analysis of the study samples.
We measured no primer cross-reaction with adenovirus en-
coding bone sialoprotein, bone morphogenetic protein-7, lu-
ciferase, noggin, PDGF-A, PDGF-1308, or GFP (data not
shown). The sensitivity and detection limit of our PCR assays
was 30 virus copies per 500ng of DNA. Within the AdPDGF-
B-treated area, viral vector could be detected within the first
week in DNA from both high-dose and low-dose treated an-
imals. The number of vector copies gradually decreased to
undetectable levels after 2 weeks (Table 3). Vector copies
measured in the blood were below the detection limit for all
animals over the total period of observation. The PCR assay
measured a low level of vector within spleen DNA of one
animal at 3 days posttreatment, andwithin the lung of another
animal at 2 weeks posttreatment; however, no significant
vector DNA was detected in organs or tissues from the treat-
ment groups for the remainder of the experimental time points
FIG. 3. Vector transduction efficiency and systemic distribution of bioluminescence. (A) Most of the luciferin signal is
restricted to the alveolar bone defect region, with minimal systemic involvement. Signals in distant organs were absent
after 14 days for both dose level groups. (B) Mild vector expression was noted during the first 3–7 days in animals treated
with AdLuc at 5.5108 PFU=ml. (C) Animals treated with AdLuc at 5.5109 PFU=ml demonstrated significant vector
expression during the first 14 days, followed by a decrease in vector expression in the head and neck region over time. The
high-dose group also showed modest vector expression in liver (one of six positive on day 14) and axillary lymph nodes
(one of six positive on day 3, and two of six positive on both days 7 and 10). Group size: n¼ 6 (three per gender). If the
intensity of bioluminescence within the region of interest was less than 5000 p=sec=cm2=sr, that region was defined as
‘‘negative’’.
SAFETY PROFILE OF AdPDGF-B IN ALVEOLAR BONE DEFECTS 493
23
(Table 3). These values were below the detection limit and
compared similarlywith vector values at the defect site, which
were low to below the detection level. On examination of
histological sections from the tissues (spleen and lung) posi-
tive for AdPDGF-B DNA, we found no inflammation-related
phenotype or other pathological findings when compared
with tissue sections from collagen matrix-treated animals.
Discussion
PDGF-BB protein has demonstrated its strong potential for
soft and hard tissue repair and is available for clinical use
(Nevins et al., 2005; Hollinger et al., 2008). However, because
of the high degradation rate and transient persistence in vivo,
the treatment outcome is not entirely predictable for clinical
applications (Kaigler et al., 2006). Gene delivery using an ad-
enoviral vector provides sustained and stable transduc-
tion efficiency in vitro (Chen and Giannobile, 2002). These
data confirm and extend those of Jin and colleagues (2004)
demonstrating significant enhancement of tooth-supporting
alveolar bone and cementum regeneration in vivo, using gene-
activated matrices containing AdPDGF-B.
Although a number of studies focus on the safety profile of
adenovirus-mediated gene therapy, few of them have ad-
dressed the local delivery of vectors using a gene-activated
matrix and none are related to the periodontium or localized
bone defects. Studies have shown that direct systemic ad-
ministration of adenoviral vectors can result in acute toxicity
and hepatic pathology (Nunes et al., 1999; Lenaerts et al., 2005;
Ni et al., 2005). Systemic dissemination can be reduced and the
efficacy-to-toxicity ratio can be improved by local gene de-
livery (Wang et al., 2005). With localized delivery, the vector
likely enters the systemic circulation via the leaky micro-
vessels and systemically disseminates within 10min (Wang
et al., 2005), with the inflammatory infiltrate within liver
observed after 15min in mice (Ni et al., 2005). In this study,
we employed matrix (collagen)-enabled gene delivery for lo-
calized administration to alveolar bone defects. The vector
dissemination in our animals beyond the alveolar bone area
was limited, demonstrating well-contained localization of the
gene-activated matrix.
Studies have shown that nearly 99% of systemically de-
livered adenoviral vectors will eventually accumulate in the
liver, and are rapidly taken up by Kupffer cells and hepato-
cytes (Hackett et al., 2000; Manickan et al., 2006). The Kupffer
cells might distribute to the lung and spleen via the circula-
tion, but in this study we did not detect any significant vector
quantities in those organs. No significant elevation of the
enzymes specific to those organs further demonstrates the
limited systemic influence of this approach. Although trans-
gene luciferase expression was found in the axillary lymph
nodes, spleen, and lungs of a few adenoviral vector-treated
animals at 2 weeks postadministration (with no expression in
these organs at later time points), the level was only slightly
greater than background and no accompanying toxicological
signs or histopathological changes were found.We also noted
no treatment-related toxicity throughout the 35-day period.
Most of the hematological and clinical chemistry parameters
were within normal ranges and the only significant difference
was noted for amylase (derived primarily from the pancreas
and parotid gland, with some from the liver), which is one
of the major enzymes to digest starch into simple sugars.
Changes in serum amylase may represent a normal physio-
logic process, acute or chronic pancreatitis, or concomitant
ongoing diseases (Garrison, 1986). However, lipase is a more
sensitive and specific marker with which to diagnose pan-
creatitis (Tietz et al., 1986), and the lipase level in all of the
animals did not change significantly. However, it is quite
possible that the amylase came from the parotid salivary
gland that was located in close proximity to the surgical field.
The parotid gland in rats is nonencapsulated, as compared
with the gland in humans. We cannot rule out this area at
Table 3. AdPDGF-B PCR Results in Bloodstream and Distant Organs
Organ=tissue Treatment No treatment Day 3 Day 7 Day 14 Day 21 Day 28 Day 35
Whole tissue
from osseous
defect
Collagen matrix N N N N N N N
5.5108 PFU=ml AdPDGF-B N 3=3 (301) 2=3 (137) 1=3 (84) N N N
5.5109 PFU=ml AdPDGF-B N 3=3 (45,930) 3=3 (6,097) N N N N
Blood Collagen matrix N N N N N N N
5.5108 PFU=ml AdPDGF-B N N N N N N N
5.5109 PFU=ml AdPDGF-B N N N N N N N
Lung Collagen matrix N N N N N N N
5.5108 PFU=ml AdPDGF-B N N N 1=3 (38) N N N
5.5109 PFU=ml AdPDGF-B N N N N N N N
Spleen Collagen matrix N N N N N N N
5.5108 PFU=ml AdPDGF-B N 1=3 (31) N N N N N
5.5109 PFU=ml AdPDGF-B N N N N N N N
Brain, SLN, ALN,
heart, liver, kidney,
sex organs (testes
or ovaries)
Collagen matrix N N N N N N N
5.5108 PFU=ml AdPDGF-B N N N N N N N
5.5109 PFU=ml AdPDGF-B N N N N N N N
Abbreviations: ALN, axillary lymph nodes; N, negative; PFU, plaque-forming units; SLN, submandibular lymph nodes.
an¼ 3 per group (for organ analyses) and 23 per group (for blood analyses). Test sample DNAs yielding signals below the limit of detection
(<30 vector particles per 500ng of DNA) are reported as negative. Entries demonstrate ‘‘positive’’ animals in each group and entries in
parentheses indicate the mean vector copy number per 500ng of DNA from the positive animals.
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early time points. At later time points when we measured the
luciferase signal from the harvested organs, no detectable
signal was found in any of the parotid glands, but mainly
in the surrounding musculature (Fig. 3). In vivo biolumines-
cence generated by expression of the luciferase transgene
permitted quantification and localization of transgene ex-
pression and provided noninvasive, dynamic, and compre-
hensive monitoring of vector expression at the whole body
level (Wood et al., 1999; Johnson et al., 2006). As little as 104
luciferase-expressing recombinant adenoviruses are capable
of producing luminescence in the liver (Honigman et al., 2001),
which is significantly higher in sensitivity than is possible
with qPCR ( Johnson et al., 2006), making bioluminescence a
more sensitive mode of evaluation of biodistribution and
subsequent vector activity. In the early time periods we de-
tected vector in the defect area of adenovirus-treated animals,
which reached undetectable levels by day 14. This result
supports those reported by Jin and colleagues (2004), showing
that the luciferase signal decreased to 20% by day 14 and
reached an undetectable level by day 28 compared with the
expression on day 1. Moreover, given that PDGF is expressed
in vivo over about 10 days in periodontal wounds after injury
(Green et al., 1997), this gene therapy approach demonstrates a
similar expression profile that may be favorable for thera-
peutic application.
In summary, the results of our experiments demonstrate
that local administration of AdPDGF-B with gene-activated
matrix is safe when delivered to tooth-supporting alveo-
lar bone defects. No treatment-related toxicity or systemic in-
volvement was found. Although vector particle DNA was
detectable during the first 2 weeks, primarily in the osseous
defects, the titer was low andquickly attenuated at subsequent
time points. These results support the further clinical devel-
opment of AdPDGF-B for regeneration therapy for oral and
craniofacial bone application.
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PDGF-B gene therapy accelerates bone engineering
and oral implant osseointegration
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Platelet-derived growth factor-BB (PDGF-BB) stimulates
repair of healing-impaired chronic wounds such as diabetic
ulcers and periodontal lesions. However, limitations in
predictability of tissue regeneration occur due, in part, to
transient growth factor bioavailability in vivo. Here, we report
that gene delivery of PDGF-B stimulates repair of oral
implant extraction socket defects. Alveolar ridge defects
were created in rats and were treated at the time of
titanium implant installation with a collagen matrix contain-
ing an adenoviral (Ad) vector encoding PDGF-B (5.5 108
or 5.5 109 pfu ml1), Ad encoding luciferase (Ad-Luc;
5.5 109 pfu ml1; control) or recombinant human PDGF-
BB protein (rhPDGF-BB, 0.3 mg ml1). Bone repair and
osseointegration were measured through backscattered
scanning electron microscopy, histomorphometry, micro-
computed tomography and biomechanical assessments.
Furthermore, a panel of local and systemic safety assess-
ments was performed. Results indicated that bone repair
was accelerated by Ad-PDGF-B and rhPDGF-BB delivery
compared with Ad-Luc, with the high dose of Ad-PDGF-B
more effective than the low dose. No significant dissemina-
tion of the vector construct or alteration of systemic param-
eters was noted. In summary, gene delivery of Ad-PDGF-B
shows regenerative and safety capabilities for bone tissue
engineering and osseointegration in alveolar bone defects
comparable with rhPDGF-BB protein delivery in vivo.
Gene Therapy (2010) 17, 95–104; doi:10.1038/gt.2009.117;
published online 10 September 2009
Keywords: dental implant; platelet-derived growth factor; regenerative medicine; virus delivery
Introduction
Oral implants are widely accepted in dental medicine as
a reconstructive treatment modality for tooth replace-
ment due to disease, injury or congenital defects. In
clinical situations exhibiting limited alveolar bone avail-
ability, growth factor application has been advocated
to improve osteogenesis and osseointegration.1 However,
as a result of the transient action and the high
degradation rate of recombinant proteins in vivo,2 the
sustained bioactivity of gene therapy vectors has been
purported to be an effective alternative for the delivery
of growth factor proteins.3,4 Adenoviral (Ad) vectors
have been shown to exhibit a high in vivo transduction
efficiency,5 with a relatively short expression period
compared with other viral-based gene delivery methods,
and their effectiveness for promoting initial wound
healing without eliciting long-term health concerns in
wound healing models).6,7
Platelet-derived growth factor (PDGF) is a potent
mitogen that facilitates wound healing8 and stimulates
bone repair by expanding osteoblastic precursor cells.9,10
PDGF-BB is Food and Drug Administration-approved for
use in the treatment of localized periodontal defects and
diabetic ulcers11–13 Ad-mediated PDGF-B (Ad-PDGF-B)
gene delivery has been shown to enhance periodontal
tissue regeneration of tooth-supporting wounds.6,14
Limited information is available regarding the potential of
PDGF-BB on promoting osseointegration of oral implants. In
addition, the influence of PDGF-B on the mechanical
integrity of an implant interface is unknown. The purpose
of this study was to investigate the effects of rhPDGF-BB
and Ad-PDGF-B delivered in a collagen matrix on the
osteogenesis and osseointegration of dental implants in an
in vivo osseointegration model. This approach shows the
ability of Ad-PDGF-B to accelerate oral implant osseointe-
gration. The data support the concept that Ad-PDGF-B gene
delivery may be an effective and safe mode of therapy
comparable with PDGF-BB application to promote dental
implant osseointegration and oral bone repair.
Results
Ad-PDGF-B and rhPDGF-BB enhance
osteogenesis in vivo
On the basis of the descriptive histology (Figure 1a), by
day 10 a gradual defect resolution was observed over
time in all groups. At days 10 and 14, woven bone and
Received 13 April 2009; revised 23 June 2009; accepted 23 June 2009;
published online 10 September 2009
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primary trabecular bone were noted at the coronal
margin (red asterisks) in Ad-Luc-treated specimens, and
thicker bone trabeculae and defect fill (DF) were evident in
all PDGF-treated specimens (black asterisks in 5.5 108 and
5.5 109 pfu ml1 Ad-PDGF-B, and rhPDGF-BB). Also at
day 14, more mature bone apposition and near-complete
DF were noted for all PDGF-treated specimens (Figure 1a,
lower panel). The histomorphometric measurements of the
5.5 109 pfu ml1 Ad-PDGF-B and rhPDGF-BB groups
showed significantly higher bone-implant contact (BIC)
than the Ad-Luc group at day 10 (Po0.05, Figure 1b).
Furthermore, all PDGF groups indicated higher DF than
the Ad-Luc group at days 10 (Po0.01, Figure 1c) and 14
(Po0.05, Figure 1c). An equivalent defect repair pattern
was noted from the backscattered scanning electron
microscopy (BS-SEM) images (Figure 2a). At day 10, BS-
SEM measurements also showed a significant difference
among all PDGF-treated groups compared with the Ad-
Luc-treated group in both bone-area fraction (BAF, Po0.05,
Figure 2b) and tissue mineral density (TMD, Po0.05,
Figure 1 Histological view of each group for 10 and 14 days (a) and two-dimensional evaluations; bone-to-implant contact (BIC) (b) and
defect fill (c). (a) Histological images were overlapped by fluorescent images made by calcein injection 3 days after surgery. The fluorescence
indicates the original defect boundaries. The results of Ad-Luc defects shows sparse bone formation at day 10 and a lesser degree of bone
maturation at 10 and 14 days. All the PDGF-related specimens showed increased new bone formation at 10 and 14 days compared with the
Ad-Luc group. Scale bar¼ 200 mm (top right panel), original magnification,  40. (b) In BIC analysis, 5.5 109 pfu ml1 Ad-PDGF-B and
rhPDGF-BB groups showed significantly higher ratio than the control group at 10 days, and 5.5 109 pfu ml in top right panel represents Ad-
PDGF-B showed significantly higher ratio than the control group at 14 days. (c) In defect fill analysis, all three PDGF treatment groups
showed higher fractions than Ad-Luc-treated defects at 10 and 14 days. Black area in left side: dental implant; black asterisks: matured new
bone; red asterisks: young new bone; and dashed line: borders of the osseous defect. Data are presented as mean and bars indicate standard
error measurement (n¼ 6–8). *Po0.05, **Po0.01, Abbreviation: BIC: bone to implant contact.
PDGF promotes dental implant osseointegration
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Figure 2c). A significant difference between rhPDGF-BB
and Ad-Luc groups in TMD was also noted at day 14
(Po0.05, Figure 3c). Completion of the DF was noted in all
the animals by day 21, and no significant differences for
any BS-SEM or histomorphometric parameters could be
found among all the groups (data not shown).
Both Ad-PDGF-B and rhPDGF-BB promote
osseointegration
The consequence of push-out testing was reflected from
the osseointegration index (OI), with all PDGF-treated
specimens showing higher scores than Ad-Luc, with
significant differences noted between rhPDGF-BB and
Ad-Luc at both days 10 and 14 (Po0.05, Figure 3a).
PDGF application tended to improve the interfacial
stiffness (IS) and maximum removal loading (MRL)
compared with the Ad-Luc group. The rhPDGF-BB
treatment indicated significantly higher IS than all other
groups at days 10 and 14 (Po0.05, Figure 3b), and higher
MRL than all other groups at day 10 (Po0.05, Figure 3c).
At day 14, the MRL of rhPDGF-BB was signifi-
cantly higher compared with both the Ad-Luc and the
5.5 109 pfu ml1 Ad-PDGF-B groups (Po0.05, Figure 3c).
Significant improvement of IS using 5.5 108 pfu ml1
Ad-PDGF-B treatment versus Ad-Luc (Po0.05, Figure 3b)
Figure 2 Backscattered SEM (BS-SEM) images (a) and two-dimensional evaluations, bone-area fraction (b), and tissue mineral density (c).
(a) BS-SEM images were merged with fluorescent images (dashed line: borders of the osseous defect.). The BS-SEM images show mineralized
tissue against the oral implant surface. (original magnification,  42) (b) The three PDGF treatment groups showed a significant difference in
bone area fraction at 10 days compared with the control group. (c) The three PDGF groups also showed significant differences in tissue
mineral density at 10 days and the rhPDGF-BB group showed significance at 14 days compared with Ad-Luc defects. Data are presented as
mean and bars indicate standard error measurement (n¼ 6–8). *Po0.05.
PDGF promotes dental implant osseointegration
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was also seen at day 10. Most day 21 specimens
experienced cortical bone fractures during the push-out
testing (suggestive of strong osseointegration), and no
significant differences among all the groups in IS and OI
scores were noted (data not shown).
Micro-computed tomography (micro-CT) images were
analyzed after implant removal, and both the
5.5 109 pfu ml1 Ad-PDGF-B and rhPDGF-BB groups
showed significantly higher bone volume fraction (BVF)
and TMD than the 5.5 108 pfu ml1 Ad-PDGF-B and
Ad-Luc groups at day 10 (Po0.05, Figure 3d and e). A
significant difference in BVF was found between
5.5 109 pfu ml1 Ad-PDGF-B and Ad-Luc groups at
day 14 (Po0.05, Figure 3d). Both the 5.5 109 pfu ml1
Ad-PDGF-B and rhPDGF-BB groups showed equi-
valent extents of functional composite tissue apparent
modulus (FCAM), which was significantly stiffer than
the 5.5 108 pfu ml1 Ad-PDGF-B or Ad-Luc group
at day 10 (Po0.05, Figure 3f). At day 14, there were
no FCAM differences between any of the treatment
groups.
Local delivery of Ad-PDGF-B shows acceptable safety
profiles in vivo
In a separate study of systemic safety, animals were
treated with collagen alone (control) or collagen contain-
ing Ad-PDGF-B (5.5 108 or 5.5 109 pfu ml1). Blood
samples were taken at various time points for hemato-
logical and clinical chemistry analyses and PCR analyses
for vector sequence. All animals survived until the day of
killing, with no progressive swelling or symptoms noted.
The majority of hematological and clinical chemistry
parameters were within their normal ranges with no
significant differences between Ad-PDGF-B and col-
lagen-only treatments (Tables 1 and 2).
Vector-specific quantitative PCR6 was carried out
on blood samples taken at baseline, days 1, 2, 3, 4, 5, 7,
14, 21, 28, and 35 after treatment. Ad-PDGF-B was not
detected in the bloodstream over the 35-day observation
period (data not shown).
Discussion
This study shows that both Ad-PDGF-B gene and
rhPDGF-BB protein delivery promote the acceleration
of neo-osteogenesis of peri-implant bony defects in vivo.
The effect on bone apposition was examined through DF
from histomorphometry (Figure 1c), BAF from BS-SEM
(Figure 2b) and BVF from micro-CT (Figure 3d). From
these results, all treatment groups, especially the
5.5 109 pfu/ml Ad-PDGF-B and rhPDGF-BB groups,
showed significantly greater bone formation compared
with the Ad-Luc vector control group at 10 days.
Regarding bone maturation, the Ad-Luc-treated defects
showed sparse and limited new bone formation and
slower bone formation within the defect area compared
with the other three groups. By day 14, in the Ad-Luc
group, new bone near the base of the defect (Figure 1a)
showed thick trabeculae and bone marrow formation,
suggesting greater maturation, whereas the thin trabe-
culae and primary woven bone-like structures at the
coronal portion of the defects suggests early-stage
Figure 3 Biomechanical and micro-CT/functional stimulations show that Ad-PDGFB and PDGF-BB improve osseointegration in vivo.
Osseointegration index (a), interfacial stiffness (b), and maximum removing load (c) showed significant differences between rhPDGF-BB
treatment and the other three groups. Bone volume fractions (d), tissue mineral density (e) and functional tissue modulus (f) show that
5.5 109 pfu ml1 Ad-PDGF-B and rhPDGF-BB groups showed significant differences compared with the 5.5 108 pfu ml1 AD-PDGF-B and
Ad-Luc groups. There were no significant differences in tissue mineral density and functional composite tissue apparent modulus (FCAM) at
day 14. Data are presented as mean and bars indicate standard error measurement (n¼ 6–8). *Po0.05.
PDGF promotes dental implant osseointegration
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osteogenesis. However, in all PDGF-treated groups,
advanced bone maturation throughout the defect area,
especially in the higher dose Ad-PDGF-B and rhPDGF-
BB groups, indicates that new bone formation initiated
earlier in those two groups compared with controls.
Taken together, these results strongly suggest that PDGF
delivery, through both the protein and the gene transfer
vector, significantly accelerated and enhanced new bone
formation in the peri-implant defects, and the higher dose
of Ad-PDGF-B showed more favorable results than lower
dosage, suggesting a dose-dependent effect on osseointe-
gration.
We also presented FCAM predicting the functional
contribution of the newly-formed bone through the FE
optimization procedures.15 It is more correlated with the
implant interfacial resistance than any single structural
parameter. Significantly, higher FCAM from the
5.5 109 pfu ml1 Ad-PDGF-B and rhPDGF-BB treat-
ment groups at day 10 indicates that both PDGF protein
and gene delivery stimulate not only osteogenesis but
also favorable initial implant function.
Two- and three-dimensional quantification results
between rhPDGF-BB and higher dose Ad-PDGF-B were
also comparable (Figures 1–3). However, the biomecha-
nical analyses did not show equivalent trends, whereas
rhPDGF-BB showed significant improvements compared
with Ad-Luc for most of the parameters (Figure 3a–c).
Although the correlation between implant stability and
peri-implant structures had been proven in previous
research,16,17 this finding may be due to the different
delivery profile of PDGF by either Ad or as a protein.
Although the initial response to a bolus administration of
rhPDGF-BB may be robust, the protein’s short half-life
results in rapid degradation within a few days,2 and
a decrease in the mitogenic response. In contrast,
Ad-PDGF-B delivery shows a delayed PDGF-BB expres-
sion profile that gradually decreases to B20% of the
highest level by day 14 in vivo.14 This finding is consistent
with a previous report whereby Ad-PDGF-B prolongs
PDGF signaling, leading to a delay with respect to timing
of osteogenic differentiation.18
The effects of PDGF on osseous wound healing have
been reported mechanistically in previous investigations.
It had been shown that PDGF signaling is important for
chemotaxis and proliferation of osteoblasts and fibro-
blasts.19,20 However, PDGF’s ability to induce osteogenic
lineage differentiation is less clear. Tokunaga et al.21
reported that PDGFRb signaling strongly inhibited
osteogenic differentiation of mesenchymal stem cells,
and Kono et al.22 further validated that the Erk signaling,
which is the subsequent PDGFR pathway, negatively
regulated osteogenesis. On the other hand, other
evidence implies that PDGF contributes to osteogenic
differentiation through a more downstream mechanism.
Huang et al.23 detected PDGF mRNA expression at both
the early proliferation stage and a late differentiation
stage of osteoprogenitor cells. Furthermore, Ng et al.24
showed that PDGFR activation was a key step for the
osteogenic lineage differentiation of mesenchymal stem
cells, whereas inhibition of PDGFbR resulted in de-
creased mineralized nodule formation. Kratchmarova
et al.25 reported that PDGF increased new bone formation
in vivo despite limited influences in osteogenic differ-
entiation in vitro. These results imply that the differentia-
tion is promoted at a certain level of expression, such as
dose- or time-dependent reactions.19,20 De Donatis et al.19
reported that a higher concentration of PDGF is favorable
for mitogenesis and lower doses for cell motility. Hsieh
and Graves20 found that pulse application of PDGF
enhances bone formation, but prolonged exposure to
PDGF limited in vitro bone regeneration. As osteogenesis
involves a cascade of events in vivo, varying strategies of
PDGF delivery must be considered for different indica-
tions. Thus, the rhPDGF-BB treatment may be suitable
for the needs of rapid bone fill, where it would quickly
recruit cells without significantly affecting the time frame
of subsequent differentiation (Supplementary Figure 1a).
The higher dose of Ad-PDGF-B may be a better choice for
a large wound site (that remains to be tested), in which
the sustained PDGF signal would attract cell progenitors
for a more extended, but still limited period of time so
that the differentiation and maturation would initiate
after PDGF signaling subsided (Supplementary Figure
1b). Given the limited size of the rat maxilla and the high
cell proliferative activity, it is necessary to further
validate this assumption in a large animal model with
more challenging, critical-size defects.
This use of gene therapy introduced a different
strategy when compared with traditional scaffold-
growth factor delivery. In our approach, the main
function of the gene-activated matrix (that is, collagen
matrix) was to mobilize the vector and allow for cell
invasion.26 The vector is then actively transfected into the
cells, followed by disintegration of capsid, condensed by
the adenovirus core proteins to enter the nucleus
(o40 nm diameter) for the subsequent expression of
the carrier gene.27 Thus, the rate-limiting step of gene
delivery was the vector transduction. High levels of
adenovirus transduction within the first 2 weeks of
delivery, and favorable regenerative effects have been
documented in several studies.6,14,28 Further efforts on
the condensation of adenovirus vector may be beneficial
for amplifying the efficiency of the gene therapy.27
The angiogenic effect of PDGF, which are similar to the
effect of vascular endothelial growth factor, may also be
favorable for osseous wound repair. During wound
healing, angiogenesis is an important event for new
tissue regeneration (that is, providing nutrients and
essential signals). The PDGFs have a similar structure to
vascular endothelial growth factor,29 and PDGF-BB
enhances fibroblast growth factor-2 stimulated vascular
endothelial growth factor release.30 PDGFRb also has an
important role in angiogenesis.31 Therefore, it is reason-
able to conclude that PDGF-BB also positively affects
angiogenesis and ultimately contributes to bone forma-
tion. Considering that dental implant function (with a
metallic non-vascularized interface) is largely dependent
on the surrounding bone quantity, quality and the
wound healing microenvironment, these accelerating
and enhancing bone formation effects of PDGF
may promote greater bone volume for earlier implant
placement and loading.
One important consideration with the use of gene
therapy vectors is the potential immune response and
related sequelae.32,33 In our study, Ad-PDGF-B was
delivered in a collagen matrix, which potentially masks
the host immune function against Ad vectors in
vivo.28,18,26,34 Typically, transformation and self-replica-
tion is eliminated by removing the E1- and E3-gene
regions of the adenovirus genome.35 We discovered no
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significant vector dissemination or alteration of hemato-
logical and clinical chemistry parameters. Our results
showed a favorable preclinical safety profile and was
comparable with our previous investigation examining
Ad-PDGF-B in periodontal defects.6 Furthermore, a non-
viral-based vector might be an alternative for delivering
the PDGF-B gene with minimal safety concerns. How-
ever, further efforts on the improvement of efficient
delivery and expression of the non-viral vectors is still
necessary.36,37
In summary, this investigation indicates the first
reported use of Ad-PDGF-B administration to promote
alveolar bone repair and osseointegration in alveolar
ridge defects. These findings suggest that Ad-PDGF-B
stimulates osseointegration that is comparable with the
delivery of PDGF-BB protein. A good safety profile was
shown supportive for extending this approach to large
animal model studies examining large critical-size bony
defects in the craniofacial complex.
Materials and methods
Experimental design
A total of 100 male Sprague–Dawley rats were used in
this study and the general timeline is shown in Figure 4a.
On the basis of the power analysis calculations from a
similar study, 6–8 animals were analyzed per treatment
per time point.14 A rat dental implant osseointegration
wound model was modified for the in vivo experiments.
A total of 82 animals were used for evaluating the effects
of osseointegration, with three time points (days 10, 14
and 21) and four treatment groups (5.5 109 pfu ml1
Ad-Luc as the control group, 5.5 108 pfu ml1 Ad-PDGF-
BB, 5.5 109 pfu ml1 Ad-PDGF-BB and 0.3 mg ml1
rhPDGF-BB) evaluated. In addition, 18 animals were
equally divided into three treatment groups (collagen
matrix alone as the control group, 5.5 108 pfu ml1 Ad-
PDGF-BB and 5.5 109 pfu ml1 Ad-PDGF-BB) and used
for determining the preclinical safety profile, with assess-
ments performed on these same animals over an obser-
vation period of 35 days.
Ad vectors and recombinant protein
Ad-PDGF-B (E1-, E3-deleted adenovirus serotype 5
encoding human platelet-derived growth factor-B) and
Ad-Luc (E1-, E3-deleted adenovirus serotype 5 encoding
firefly luciferase) have been previously described.6 In
both vectors, transgene expression is under control of the
CMV promoter. Titers of virus stocks were determined
on embryonic kidney 293 cells by plaque assay and
expressed as the particle number per milliliter.7 The
rhPDGF-BB was purchased from Biomimetic Therapeu-
tics Inc. (Franklin, TN, USA) at a working concentration
of 0.5 mg ml1.
Preparation of vector/protein-gene activated matrix
Ad-PDGF-B, Ad-Luc and rhPDGF-BB were dialyzed into
GTS buffer (2.5% glycerol, 25 mM NaCl, 20 mM Tris, pH
8.0) and formulated in bovine fibrillar type I collagen
matrix (Matrix Pharmaceutical Inc., Fremont, CA, USA)
at a final concentration of 2.6%.
Figure 4 Experimental design (a) and experimental model illustration (b). Implant surgery was performed 4 weeks following maxillary first
molar extraction. To create a consistent and reproducible defect, custom-made step drills were used. After dental implant placement, the bone
defect was filled with 5.5 109 pfu ml1 Ad-Luc, 5.5 108 pfu ml1 Ad-PDGF-B, 5.5 109 pfu ml1 Ad-PDGF-B or 0.3 mg ml1 rhPDGF-BB
formulated with the collagen matrix for evaluating osseointegration (n¼ 6–8 per group per time point). Histomorphometric and BS-SEM
measurements were done at days 10, 14 and 21 after implant installation, and three-dimensional evaluations (micro-CT imaging) as well as
functional assessments (biomechanical testing and functional simulations) were done at days 10, 14 and 21 after implant installation. For
evaluating the safety profile, the bone defect was filled with 5.5 108 pfu ml1 Ad-PDGF-B, 5.5 109 pfu ml1 Ad-PDGF-B or collagen matrix
alone. The hematology, chemical chemistry and vector dissemination were evaluated over a period of 35 days (n¼ 6 per group per time
point).
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Animal model for evaluating therapeutic effects
All animal procedures followed the guidelines from
the Committee on Use and Care of Animals of the
University of Michigan. The maxillary first molars were
extracted bilaterally 4 weeks before dental implant
installation. After healing, an osteotomy was created using
a custom drill-bit by a single surgeon (Y-JS). The drill-bit
was designed with a 0.95-mm diameter, 1 mm long-apical
portion and a 2.2-mm diameter, 1 mm long at the coronal
aspect (Figure 4b). The apical part of the drill created an
osteotomy for initial fixation and the coronal part of the
drill created a circumferential osseous defect before dental
implant installation. A custom cylinder-type titaniummini-
implant (kind gift of Institut Straumann AG, Basel,
Switzerland), 1 mm in diameter and 2 mm in depth, was
press-fit into the surgically created socket (Figure 4b).
The remaining defect was then filled with the type I
collagen matrix containing 5.5 109 pfu ml1 Ad-Luc,
5.5 108 pfu ml1 Ad-PDGF-B, 5.5 109 pfu ml1 Ad-
PDGF-B or 0.3 mg ml1 rhPDGF-BB (Figure 4b). Ad-Luc
has not previously exhibited biological activities in den-
toalveolar defects14 and served as a control group in this
study. The surgical area was covered by gingival tissue and
re-approximated using butyl cyanoacrylate (Periacryl,
Glustitch Inc., Point Roberts, WA, USA). The vital fluoro-
chrome dye, calcein (10 mg kg1), was injected intramus-
cularly after 3 days, and antibiotics (268 mg l1 ampicillin
in 5% dextrose water) were provided during the first 7
days after operation.
BS-SEM and histology
Coded maxillae containing the implants were harvested
upon killing, with one side of maxillae taken for BS-SEM
and histology, whereas the contralateral maxillae were
used for biomechanical assessments (see following
section). The specimens were fixed in 50% ethanol for
at least 72 h and subsequently embedded in epoxy resin.
The specimens were then sectioned in the longitudinal
direction relative to the implants using a diamond saw
blade (Crystalite Co., Westerville OH, USA), then
polished to achieve a 50- to 100-mm final thickness. The
tissue mineralization was evaluated under the back-
scattered mode on Qanta F1B SEM with  45 magnifica-
tion, calibrated with aluminum and carbon discs,38
and transferred to physical density using bone subs-
titute radiographic phantoms (Gammex Inc., Middleton
WI, USA). The photographs were then segmented
and threshholded by Otsu’s adaptive technique.39
To eliminate any metal scattering effect, the measured
bone-implant interface was defined as the horizontal
distance 5 mm from the outermost homogenous high-
intensity area. The defect borders were projected using
the calcein fluorescent images. BAF (the ratio of newly
formed bone in the defect to the entire defect area) and
TMD within the defect (the average grayscale level of
mineralized tissue within the defect area) were measu-
red from BS-SEM images. Next, histological staining
by methylene blue was performed, with the acid
fuschin used as the counterstain.28 BIC (the ratio of the
length of bone contacting the titanium to the entire
length of titanium interface with the defect area) and
DF (the ratio of bone-occupied area to the entire
defect area) were measured by calibrated examiners
P-CC and Y-JS).
Biomechanical, three-dimensional radiographic and
functional evaluations
The remaining maxillae were used for biomechanical
and micro-CT evaluation and stored in normal saline
at 20 1C to preserve the mechanical integrity. After
thawing at room temperature, the specimens were
rapidly secured in acrylic resin. The mini-implants were
meticulously pushed out of each maxilla using an MTS
machine (Model 858, Mini-Bionix II, MTS Systems Corp.,
Eden Prairie, MN, USA) at a constant displacement rate
of 0.1 mm s1, while recording the load–displacement
relationship of the top of implant during the push-out
procedures. The region from 20 to 80% of the MRL was
chosen and a linear regression was performed to
calculate the IS. A previously described OI based on
the nature of the bone fail during implant push-out tests
was also used to further document the interfacial
biomechanical behavior (Supplementary Table S1).15
After implant push-out, micro-CT scans were per-
formed using an eXplore Locus SP Micro-CT system (GE
HealthCare, London, ON, Canada) and reconstructed to
the voxel size of 18 mm 18 mm 18 mm. The spatial
relationship of the mini-implant and surrounding tissues
was then analyzed using a customized MATLAB (Math-
works Inc., Natick, MA, USA) algorithm. The images
were segmented with a threshold determined by Otsu’s
adaptive technique,39 and several parameters were
quantitatively evaluated within the osseous defect areas:
(1) BVF: the volume of mineralized tissue within the
osseous wound divided by the volume of osseous
wound; (2) TMD: the mineral content of the radio-
graphic-defined mineralized tissue within the osseous
wound divided by the volume of osseous wound; (3)
bone mineral density: the mineral density within the
radiographic-defined mineralized tissue in the osseous
wound. After micro-CT evaluations, the images were
transferred to create a finite element (FE) mesh, and the
functional bone modulus (referring to the rigidity of
bone within the area of interest toward dental implant)
and FCAM (rigidity of the whole tissue within the area of
interest toward dental implant) were generated from
previously described simulation procedures.15
Safety profile determination
A total of 18 male Sprague–Dawley rats had their
first maxillary molars extracted, osseous defect created
and implant placement as previously described.28 The
osseous defects were filled with the type I collagen
vehicle alone, or containing Ad-PDGF-B (5.5 108 or
5.5 109 pfu ml1). Another six animals without any
surgical treatments were also included to provide base-
line parameters. Blood was drawn from rat tail veins at
baseline and at 1, 2, 3, 4, 5, 6, 7, 14, 21, 28 and 35 days.
Hematological and clinical chemistry parameters (listed
in Table 1) were examined at baseline and at 3, 7, 14, 21,
28 and 35 days. Vector dissemination was evaluated for
all blood draw time points. Genomic DNA was isolated
from 50 ml whole blood using QIAamp DNA Blood Mini
kit (Qiagen Inc., Valencia, CA, USA), and quantitative
TaqMan PCR was used to determine the copies of Ad-
PDGF-B in the bloodstream. The primers used for qPCR
bridging the vector backbone and PDGF-B prepro region
were as follows: sense, 50-GGATCTTCGAGTCGACA
AGCTT-30; anti-sense, 50-ATCTCATAAAGCTCCTCG
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GGAAT-30; and internal fluorogenic probe, 50-CGC
CCAGCAGCGATTCATGGTGAT-30. The resulting amp-
licon was detected by ABI Prism 7700 sequence detection
instrument (Applied Biosystems, Foster City, CA, USA),
and the thermal condition was as follows: 50 1C for
2 min, 95 1C at 10 min followed by 45 cycles of 95 1C for
15 s and 60 1C for 1 min. The assay sensitivity was 30
copies per 500 ng DNA. There was no cross-reaction with
Ad vector encoding PDGF-A, PDGF-1308 (dominant-
negative, PDGF mutant), bone morphogenetic protein-7,
noggin, bone sialoprotein, Ad-Luc or green fluorescent
protein.
Statistical analysis
One-way ANOVA with Tukey test was used to analyze
the difference of coded specimens for histomorpho-
metric, BS-SEM, micro-CT, biomechanical and functional
parameters between PDGF-treated (collagen containing
0.3 mg ml1 rhPDGF-BB, 5.5 108 or 5.5 109 pfu ml1
Ad-PDGF-B) and non-PDGF-treated (collagen alone)
groups at each time point. For evaluating the safety
profile, the difference of vector replicates, hematological
and chemical parameters between experimental groups
(collagen containing 5.5 108 or 5.5 109 pfu ml1
Ad-PDGF-B) were evaluated for time-dependent dy-
namics with the control (collagen alone) group using
Bonferroni post-tests, and the significance was assessed
by repeated-measures ANOVA. The statistical difference
was considered with a P-value of o0.05.
Conflict of interest
Lois A Chandler and Barbara Sosnowski are employees
of Tissue Repair Company. Steven A Goldstein may
receive royalties if distributed by the University of
Michigan, and the University of Michigan may benefit
from the subject of this paper, as a result of the
technology that was licensed to Tissue Repair Company.
William Giannobile has financial interest in BioMimetic
Therapeutics, Inc.
Acknowledgements
We thank Valeria Pontelli Navarro Tedeschi for assis-
tance with animal surgeries, Dennis Kayner for assisting
removal of the implants, Dr. Noboru Kikuchi for
establishing finite element models and Anna Colvig for
performing hematological and clinical chemical exam-
inations. This study was supported in part by the grants
from the National Institutes of Health (NIH)/National
Institute of Dental and Craniofacial Research (NIDCR)
(R01-DE13397) and the AO Foundation Research Advi-
sory Council (Davos, Switzerland) to WVG.
References
1 Wikesjo UM, Sorensen RG, Wozney JM. Augmentation of
alveolar bone and dental implant osseointegration: clinical
implications of studies with rhBMP-2. J Bone Joint Surg Am
2001; 83-A (Suppl 1): S136–S145.
2 Lynch SE, de Castilla GR, Williams RC, Kiritsy CP, Howell TH,
Reddy MS et al. The effects of short-term application of a
combination of platelet-derived and insulin-like growth factors
on periodontal wound healing. J Periodontol 1991; 62: 458–467.
3 Fang J, Zhu YY, Smiley E, Bonadio J, Rouleau JP, Goldstein SA
et al. Stimulation of new bone formation by direct transfer
of osteogenic plasmid genes. Proc Natl Acad Sci USA 1996; 93:
5753–5758.
4 Ramseier CA, Abramson ZR, Jin Q, Giannobile WV. Gene
therapeutics for periodontal regenerative medicine. Dent Clin
North Am 2006; 50: 245–263, ix.
5 Ghosh SS, Gopinath P, Ramesh A. Adenoviral vectors: a
promising tool for gene therapy. Appl Biochem Biotechnol 2006;
133: 9–29.
6 Chang PC, Cirelli JA, Jin Q, Seol YJ, Sugai JV, D’Silva NJ et al.
Adenovirus encoding human platelet-derived growth factor-B
delivered to alveolar bone defects exhibits safety and biodis-
tribution profiles favorable for clinical use. Hum Gene Ther 2009;
20: 486–496.
7 Gu DL, Nguyen T, Gonzalez AM, Printz MA, Pierce GF,
Sosnowski BA et al. Adenovirus encoding human platelet-
derived growth factor-B delivered in collagen exhibits safety,
biodistribution, and immunogenicity profiles favorable for
clinical use. Mol Ther 2004; 9: 699–711.
8 Barrientos S, Stojadinovic O, Golinko MS, Brem H, Tomic-Canic
M. Growth factors and cytokines in wound healing. Wound
Repair Regen 2008; 16: 585–601.
9 Anusaksathien O, Jin Q, Zhao M, SomermanMJ, Giannobile WV.
Effect of sustained gene delivery of platelet-derived growth
factor or its antagonist (PDGF-1308) on tissue-engineered
cementum. J Periodontol 2004; 75: 429–440.
10 Canalis E, McCarthy TL, Centrella M. Effects of platelet-derived
growth factor on bone formation in vitro. J Cell Physiol 1989; 140:
530–537.
11 Nevins M, Giannobile WV, McGuire MK, Kao RT, Mellonig JT,
Hinrichs JE et al. Platelet-derived growth factor stimulates bone
fill and rate of attachment level gain: results of a large
multicenter randomized controlled trial. J Periodontol 2005; 76:
2205–2215.
12 Uhl E, Rosken F, Sirsjo A, Messmer K. Influence of platelet-
derived growth factor on microcirculation during normal
and impaired wound healing. Wound Repair Regen 2003; 11:
361–367.
13 Simion M, Rocchietta I, Monforte M, Maschera E. Three-
dimensional alveolar bone reconstruction with a combination
of recombinant human platelet-derived growth factor BB and
guided bone regeneration: a case report. Int J Periodontics
Restorative Dent 2008; 28: 239–243.
14 Jin Q, Anusaksathien O, Webb SA, Printz MA, Giannobile WV.
Engineering of tooth-supporting structures by delivery of PDGF
gene therapy vectors. Mol Ther 2004; 9: 519–526.
15 Chang PC, Seol YJ, Kikuchi N, Goldstein SA, Giannobile WV.
Functional apparent moduli: Indicators to predict dynamics of
oral implant osseointegration (in review).
16 Gabet Y, Mu¨ller R, Levy J, Dimarchi R, Chorev M, Bab I et al.
Parathyroid hormone 1-34 enhances titanium implant anchorage
in low-density trabecular bone: a correlative micro-computed
tomographic and biomechanical analysis. Bone 2006; 39:
276–282.
17 Ramp LC, Jeffcoat RL. Dynamic behavior of implants as a
measure of osseointegration. Int J Oral Maxillofac Implants 2001;
16: 637–645.
18 Lin Z, Sugai JV, Jin Q, Chandler LA, Giannobile WV. Platelet-
derived growth factor-B gene delivery sustains gingival fibro-
blast signal transduction. J Periodontal Res 2008; 43: 440–449.
19 De Donatis A, Comito G, Buricchi F, Vinci MC, Parenti A, Caselli
A et al. Proliferation versus migration in platelet-derived growth
factor signaling: the key role of endocytosis. J Biol Chem 2008;
283: 19948–19956.
PDGF promotes dental implant osseointegration
P-C Chang et al
103
Gene Therapy36
20 Hsieh SC, Graves DT. Pulse application of platelet-derived
growth factor enhances formation of a mineralizing matrix
while continuous application is inhibitory. J Cell Biochem 1998;
69: 169–180.
21 Tokunaga A, Oya T, Ishii Y, Motomura H, Nakamura C,
Ishizawa S et al. PDGF receptor beta is a potent regulator of
mesenchymal stromal cell function. J Bone Miner Res 2008; 23:
1519–1528.
22 Kono SJ, Oshima Y, Hoshi K, Bonewald LF, Oda H, Nakamura K
et al. Erk pathways negatively regulate matrix mineralization.
Bone 2007; 40: 68–74.
23 Huang Z, Nelson ER, Smith RL, Goodman SB. The sequential
expression profiles of growth factors from osteoprogenitors
(correction of osteroprogenitors) to osteoblasts in vitro. Tissue
Eng 2007; 13: 2311–2320.
24 Ng F, Boucher S, Koh S, Sastry KS, Chase L, Lakshmipathy U
et al. PDGF, TGF-beta, and FGF signaling is important
for differentiation and growth of mesenchymal stem cells
(MSCs): transcriptional profiling can identify markers and
signaling pathways important in differentiation of MSCs into
adipogenic, chondrogenic, and osteogenic lineages. Blood 2008;
112: 295–307.
25 Kratchmarova I, Blagoev B, Haack-Sorensen M, Kassem M,
Mann M. Mechanism of divergent growth factor effects
in mesenchymal stem cell differentiation. Science 2005; 308:
1472–1477.
26 Doukas J, Chandler LA, Gonzalez AM, Gu D, Hoganson DK, Ma
C et al.Matrix immobilization enhances the tissue repair activity
of growth factor gene therapy vectors. Hum Gene Ther 2001; 12:
783–798.
27 Pouton CW, Wagstaff KM, Roth DM, Moseley GW, Jans DA.
Targeted delivery to the nucleus. Adv Drug Deliv Rev 2007; 59:
698–717.
28 Dunn CA, Jin Q, Taba Jr M, Franceschi RT, Bruce Rutherford R,
Giannobile WV. BMP gene delivery for alveolar bone
engineering at dental implant defects. Mol Ther 2005; 11:
294–299.
29 Andrae J, Gallini R, Betsholtz C. Role of platelet-derived
growth factors in physiology and medicine. Genes Dev 2008;
22: 1276–1312.
30 Tokuda H, Takai S, Hanai Y, Harada A, Matsushima-Nishiwaki
R, Kato H et al. Potentiation by platelet-derived growth factor-BB
of FGF-2-stimulated VEGF release in osteoblasts. J Bone Miner
Metab 2008; 26: 335–341.
31 Zhang J, Cao R, Zhang Y, Jia T, Cao Y, Wahlberg E. Differential
roles of PDGFR-{alpha} and PDGFR-{beta} in angiogenesis and
vessel stability. FASEB J 2008; 23: 153–163.
32 Douglas JT. Adenoviral vectors for gene therapy. Mol Biotechnol
2007; 36: 71–80.
33 Hartman ZC, Appledorn DM, Amalfitano A. Adenovirus vector
induced innate immune responses: impact upon efficacy and
toxicity in gene therapy and vaccine applications. Virus Res 2008;
132: 1–14.
34 Sonobe J, Okubo Y, Kaihara S, Miyatake S, Bessho K.
Osteoinduction by bone morphogenetic protein 2-expressing
adenoviral vector: application of biomaterial to mask the host
immune response. Hum Gene Ther 2004; 15: 659–668.
35 Wang Y, Yang Z, Liu S, Kon T, Krol A, Li CY et al.
Characterisation of systemic dissemination of nonreplicating
adenoviral vectors from tumours in local gene delivery. Br J
Cancer 2005; 92: 1414–1420.
36 Paleos CM, Tziveleka LA, Sideratou Z, Tsiourvas D. Gene
delivery using functional dendritic polymers. Expert Opin Drug
Deliv 2009; 6: 27–38.
37 Ditto AJ, Shah PN, Gump LR, Yun YH. Nanospheres formulated
from l-tyrosine polyphosphate exhibiting sustained release of
polyplexes and in vitro controlled transfection properties. Mol
Pharm 2009; 6: 986–995.
38 Traini T, Degidi M, Iezzi G, Artese L, Piattelli A. Comparative
evaluation of the peri-implant bone tissue mineral density
around unloaded titanium dental implants. J Dent 2007; 35:
84–92.
39 Otsu N. Threshold selection method from gray-level histograms.
IEEE Trans Syst Man Cybern 1979; 9: 62–66.
Supplementary Information accompanies the paper on Gene Therapy website (http://www.nature.com/gt)
PDGF promotes dental implant osseointegration
P-C Chang et al
104
Gene Therapy 37
 38
REFERENCES 
1. WinterGreen Research, I. Worldwide Nanotechnology Dental Implant Market Shares, 
Strategies, and Forecasts, 2009 to 2015. 2009. 
2. Schwartz, N. L., Whitsett, L. D., Berry, T. G., and Stewart, J. L. Unserviceable crowns and 
fixed partial dentures: life-span and causes for loss of serviceability. J Am Dent Assoc, 81: 
1395-1401, 1970. 
3. Carr, A. B. and Laney, W. R. Maximum occlusal force levels in patients with 
osseointegrated oral implant prostheses and patients with complete dentures. Int J Oral 
Maxillofac Implants, 2: 101-108, 1987. 
4. Carlsson, G. E., Lindquist, L. W., and Jemt, T. Long-term marginal periimplant bone loss 
in edentulous patients. Int J Prosthodont, 13: 295-302, 2000. 
5. Schropp, L., Wenzel, A., Kostopoulos, L., and Karring, T. Bone healing and soft tissue 
contour changes following single-tooth extraction: a clinical and radiographic 12-month 
prospective study. Int J Periodontics Restorative Dent, 23: 313-323, 2003. 
6. Buser, D., Martin, W., and Belser, U. C. Optimizing esthetics for implant restorations in 
the anterior maxilla: anatomic and surgical considerations. Int J Oral Maxillofac Implants, 
19 Suppl: 43-61, 2004. 
7. Hammerle, C. H. and Glauser, R. Clinical evaluation of dental implant treatment. 
Periodontol 2000, 34: 230-239, 2004. 
8. Becker, W., Lynch, S. E., Lekholm, U., Becker, B. E., Caffesse, R., Donath, K., and 
Sanchez, R. A comparison of ePTFE membranes alone or in combination with 
platelet-derived growth factors and insulin-like growth factor-I or demineralized 
 39
freeze-dried bone in promoting bone formation around immediate extraction socket 
implants. J Periodontol, 63: 929-940, 1992. 
9. Giannobile, W. V., Finkelman, R. D., and Lynch, S. E. Comparison of canine and 
non-human primate animal models for periodontal regenerative therapy: results following 
a single administration of PDGF/IGF-I. J Periodontol, 65: 1158-1168, 1994. 
10. Giannobile, W. V., Hernandez, R. A., Finkelman, R. D., Ryan, S., Kiritsy, C. P., D'Andrea, 
M., and Lynch, S. E. Comparative effects of platelet-derived growth factor-BB and 
insulin-like growth factor-I, individually and in combination, on periodontal regeneration 
in Macaca fascicularis. J Periodontal Res, 31: 301-312, 1996. 
11. Park, J. B., Matsuura, M., Han, K. Y., Norderyd, O., Lin, W. L., Genco, R. J., and Cho, M. 
I. Periodontal regeneration in class III furcation defects of beagle dogs using guided tissue 
regenerative therapy with platelet-derived growth factor. J Periodontol, 66: 462-477, 1995. 
12. Rutherford, R. B., Niekrash, C. E., Kennedy, J. E., and Charette, M. F. Platelet-derived and 
insulin-like growth factors stimulate regeneration of periodontal attachment in monkeys. J 
Periodontal Res, 27: 285-290, 1992. 
13. Howell, T. H., Fiorellini, J. P., Paquette, D. W., Offenbacher, S., Giannobile, W. V., and 
Lynch, S. E. A phase I/II clinical trial to evaluate a combination of recombinant human 
platelet-derived growth factor-BB and recombinant human insulin-like growth factor-I in 
patients with periodontal disease. J Periodontol, 68: 1186-1193, 1997. 
14. Nevins, M., Giannobile, W. V., McGuire, M. K., Kao, R. T., Mellonig, J. T., Hinrichs, J. E., 
McAllister, B. S., Murphy, K. S., McClain, P. K., Nevins, M. L., Paquette, D. W., Han, T. 
J., Reddy, M. S., Lavin, P. T., Genco, R. J., and Lynch, S. E. Platelet-derived growth factor 
 40
stimulates bone fill and rate of attachment level gain: results of a large multicenter 
randomized controlled trial. J Periodontol, 76: 2205-2215, 2005. 
15. Anusaksathien, O. and Giannobile, W. V. Growth factor delivery to re-engineer 
periodontal tissues. Curr Pharm Biotechnol, 3: 129-139, 2002. 
16. Bonadio, J. Tissue engineering via local gene delivery: update and future prospects for 
enhancing the technology. Adv Drug Deliv Rev, 44: 185-194, 2000. 
17. Boyne, P. J., Marx, R. E., Nevins, M., Triplett, G., Lazaro, E., Lilly, L. C., Alder, M., and 
Nummikoski, P. A feasibility study evaluating rhBMP-2/absorbable collagen sponge for 
maxillary sinus floor augmentation. Int J Periodontics Restorative Dent, 17: 11-25, 1997. 
18. Cochran, D. L., Jones, A. A., Lilly, L. C., Fiorellini, J. P., and Howell, H. Evaluation of 
recombinant human bone morphogenetic protein-2 in oral applications including the use of 
endosseous implants: 3-year results of a pilot study in humans. J Periodontol, 71: 
1241-1257, 2000. 
19. van den Bergh, J. P., ten Bruggenkate, C. M., Groeneveld, H. H., Burger, E. H., and 
Tuinzing, D. B. Recombinant human bone morphogenetic protein-7 in maxillary sinus 
floor elevation surgery in 3 patients compared to autogenous bone grafts. A clinical pilot 
study. J Clin Periodontol, 27: 627-636, 2000. 
20. Terrell, T. G., Working, P. K., Chow, C. P., and Green, J. D. Pathology of recombinant 
human transforming growth factor-beta 1 in rats and rabbits. Int Rev Exp Pathol, 34 Pt B: 
43-67, 1993. 
21. Langer, R. Drug delivery and targeting. Nature, 392: 5-10, 1998. 
 41
22. Murphy, K. G. and Gunsolley, J. C. Guided tissue regeneration for the treatment of 
periodontal intrabony and furcation defects. A systematic review. Ann Periodontol, 8: 
266-302, 2003. 
23. Reynolds, M. A., Aichelmann-Reidy, M. E., Branch-Mays, G. L., and Gunsolley, J. C. The 
efficacy of bone replacement grafts in the treatment of periodontal osseous defects. A 
systematic review. Ann Periodontol, 8: 227-265, 2003. 
24. Jin, Q., Anusaksathien, O., Webb, S. A., Printz, M. A., and Giannobile, W. V. Engineering 
of tooth-supporting structures by delivery of PDGF gene therapy vectors. Mol Ther, 9: 
519-526, 2004. 
25. Dunn, C. A., Jin, Q., Taba, M., Jr., Franceschi, R. T., Bruce Rutherford, R., and Giannobile, 
W. V. BMP gene delivery for alveolar bone engineering at dental implant defects. Mol 
Ther, 11: 294-299, 2005. 
26. Gu, D. L., Nguyen, T., Gonzalez, A. M., Printz, M. A., Pierce, G. F., Sosnowski, B. A., 
Phillips, M. L., and Chandler, L. A. Adenovirus encoding human platelet-derived growth 
factor-B delivered in collagen exhibits safety, biodistribution, and immunogenicity 
profiles favorable for clinical use. Mol Ther, 9: 699-711, 2004. 
27. Ostman, A. and Heldin, C. H. Involvement of platelet-derived growth factor in disease: 
development of specific antagonists. Adv Cancer Res, 80: 1-38, 2001. 
28. Kaplan, D. R., Chao, F. C., Stiles, C. D., Antoniades, H. N., and Scher, C. D. Platelet alpha 
granules contain a growth factor for fibroblasts. Blood, 53: 1043-1052, 1979. 
29. Seppa, H., Grotendorst, G., Seppa, S., Schiffmann, E., and Martin, G. R. Platelet-derived 
growth factor in chemotactic for fibroblasts. J Cell Biol, 92: 584-588, 1982. 
 42
30. Heldin, P., Laurent, T. C., and Heldin, C. H. Effect of growth factors on hyaluronan 
synthesis in cultured human fibroblasts. Biochem J, 258: 919-922, 1989. 
31. Rosenkranz, S. and Kazlauskas, A. Evidence for distinct signaling properties and 
biological responses induced by the PDGF receptor alpha and beta subtypes. Growth 
Factors, 16: 201-216, 1999. 
32. Heldin, C. H., Ostman, A., and Ronnstrand, L. Signal transduction via platelet-derived 
growth factor receptors. Biochim Biophys Acta, 1378: F79-113, 1998. 
33. Kaminski, W. E., Lindahl, P., Lin, N. L., Broudy, V. C., Crosby, J. R., Hellstrom, M., 
Swolin, B., Bowen-Pope, D. F., Martin, P. J., Ross, R., Betsholtz, C., and Raines, E. W. 
Basis of hematopoietic defects in platelet-derived growth factor (PDGF)-B and PDGF 
beta-receptor null mice. Blood, 97: 1990-1998, 2001. 
34. Parkar, M. H., Kuru, L., Giouzeli, M., and Olsen, I. Expression of growth-factor receptors 
in normal and regenerating human periodontal cells. Arch Oral Biol, 46: 275-284, 2001. 
35. Green, R. J., Usui, M. L., Hart, C. E., Ammons, W. F., and Narayanan, A. S. 
Immunolocalization of platelet-derived growth factor A and B chains and PDGF-alpha and 
beta receptors in human gingival wounds. J Periodontal Res, 32: 209-214, 1997. 
36. Nishimura, F. and Terranova, V. P. Comparative study of the chemotactic responses of 
periodontal ligament cells and gingival fibroblasts to polypeptide growth factors. J Dent 
Res, 75: 986-992, 1996. 
37. Oates, T. W., Rouse, C. A., and Cochran, D. L. Mitogenic effects of growth factors on 
human periodontal ligament cells in vitro. J Periodontol, 64: 142-148, 1993. 
 43
38. Haase, H. R., Clarkson, R. W., Waters, M. J., and Bartold, P. M. Growth factor modulation 
of mitogenic responses and proteoglycan synthesis by human periodontal fibroblasts. J 
Cell Physiol, 174: 353-361, 1998. 
39. Matsuda, N., Lin, W. L., Kumar, N. M., Cho, M. I., and Genco, R. J. Mitogenic, 
chemotactic, and synthetic responses of rat periodontal ligament fibroblastic cells to 
polypeptide growth factors in vitro. J Periodontol, 63: 515-525, 1992. 
40. Zaman, K. U., Sugaya, T., and Kato, H. Effect of recombinant human platelet-derived 
growth factor-BB and bone morphogenetic protein-2 application to demineralized dentin 
on early periodontal ligament cell response. J Periodont Res, 34: 244-250, 1999. 
41. Lynch, S. E., de Castilla, G. R., Williams, R. C., Kiritsy, C. P., Howell, T. H., Reddy, M. S., 
and Antoniades, H. N. The effects of short-term application of a combination of 
platelet-derived and insulin-like growth factors on periodontal wound healing. J 
Periodontol., 62: 458-467, 1991. 
42. Camelo, M., Nevins, M. L., Schenk, R. K., Lynch, S. E., and Nevins, M. Periodontal 
regeneration in human Class II furcations using purified recombinant human 
platelet-derived growth factor-BB (rhPDGF-BB) with bone allograft. Int J Periodontics 
Restorative Dent, 23: 213-225, 2003. 
43. Steed, D. L. Clinical evaluation of recombinant human platelet-derived growth factor for 
the treatment of lower extremity ulcers. Plast Reconstr Surg, 117: 143S-149S; discussion 
150S-151S, 2006. 
44. Cooke, J. W., Sarment, D. P., Whitesman, L. A., Miller, S. E., Jin, Q., Lynch, S. E., and 
Giannobile, W. V. Effect of rhPDGF-BB delivery on mediators of periodontal wound 
repair. Tissue Eng, 12: 1441-1450, 2006. 
 44
45. Sarment, D. P., Cooke, J. W., Miller, S. E., Jin, Q., McGuire, M. K., Kao, R. T., McClain, 
P. K., McAllister, B. S., Lynch, S. E., and Giannobile, W. V. Effect of rhPDGF-BB on 
bone turnover during periodontal repair. J Clin Periodontol, 33: 135-140, 2006. 
46. Giannobile, W. V., Lee, C. S., Tomala, M. P., Tejeda, K. M., and Zhu, Z. Platelet-derived 
growth factor (PDGF) gene delivery for application in periodontal tissue engineering. J 
Periodontol, 72: 815-823, 2001. 
47. Zhu, Z., Lee, C. S., Tejeda, K. M., and Giannobile, W. V. Gene transfer and expression of 
platelet-derived growth factors modulate periodontal cellular activity. J Dent Res, 80: 
892-897, 2001. 
48. Anusaksathien, O., Webb, S. A., Jin, Q. M., and Giannobile, W. V. Platelet-derived growth 
factor gene delivery stimulates ex vivo gingival repair. Tissue Eng, 9: 745-756, 2003. 
49. Jin, Q. M., Anusaksathien, O., Webb, S. A., Rutherford, R. B., and Giannobile, W. V. Gene 
therapy of bone morphogenetic protein for periodontal tissue engineering. J Periodontol, 
74: 202-213, 2003. 
50. Traini, T., Degidi, M., Iezzi, G., Artese, L., and Piattelli, A. Comparative evaluation of the 
peri-implant bone tissue mineral density around unloaded titanium dental implants. J Dent, 
35: 84-92, 2007. 
51. Otsu, N. A threshold selection method from gray-level histograms. IEEE Trans. Sys., Man., 
Cyber., 9: 62-66, 1979. 
 
 
 
 
